

Remington's Pharmaceutical Sciences

17

17TH
EDITION

Remington's

ALFONSO R GENNARO

*Editor, and Chairman
of the Editorial Board*

"A WINNER NEVER QUILS, AND A QUITTER
NEVER WINS"

Pharmaceutical Sciences

1985

MACK PUBLISHING COPMANY

Easton, Pennsylvania 18042

TEVA EXHIBIT 1030
TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC

CHAPTER 37

Drug Absorption, Action, and Disposition

Stewart C Harvey, PhD

Professor of Pharmacology
School of Medicine, University of Utah
Salt Lake City, UT 84132

Although drugs differ widely in their pharmacodynamic effects and clinical application, in penetrance, absorption, and usual route of administration, in distribution among the body tissues, and in disposition and mode of termination of action, there are certain general principles that help explain these differences. These principles have both pharmacologic and therapeutic implications. They facilitate an understanding of both the features that are common to a class of drugs and the differentia among the members of that class.

In order for a drug to act it must be absorbed, transported to the appropriate tissue or organ, penetrate to the responding subcellular structure, and elicit a response or alter ongoing processes. The drug may be simultaneously or sequentially distributed to a number of tissues; bound or stored, metabolized to inactive or active products, or excreted. The history of a drug in the body is summarized in Fig 37-1. Each of the processes or events depicted relates importantly to therapeutic and toxic effects of a drug and to the mode of administration, and drug design must take each into account. Since the effect elicited by a drug is its *raison d'être*, *drug action* and *effect* will be discussed first in the text that follows, even though they are preceded by other events.




Fig 37-1. The absorption, distribution, action, and elimination of a drug (arrows represent drug movement). Intravenous administration is the only process whereby a drug may enter a compartment without passing through a biological membrane. Note that drugs excreted in bile and saliva may be resorbed.

Drug Action and Effect

The word *drug* imposes an action-effect context within which the properties of a substance are described. The description must of necessity include the pertinent properties of the recipient of the drug. Thus, when a drug is defined as an analgesic, it is implied that the recipient reacts in a certain way, called pain,* to a noxious stimulus. Both because the pertinent properties are locked into the complex and somewhat imprecise biological context and because the types of possible response are many, descriptions of the properties of drugs tend to emphasize the qualitative features of the effects they elicit. Thus a drug may be described as having analgesic, vasodepressor, convulsant, antibacterial, etc., properties. The specific effect (or use) categories into which the many drugs may be placed are the subject of Chapters 40 through 67 and will not be elaborated upon in this chapter. However, the description of a drug does not end with the enumeration of the responses it may elicit. There are certain intrinsic properties of the drug-recipient system that can be described in quantitative terms and which are essential to the full description of the drug and to the validation of the drug for specific uses. Under *Definitions and Concepts*, below, certain general terms are defined in qualitative language; under *Dose-Effect Relationships* the foundation is laid for an appreciation of some of the quantitative aspects of pharmacodynamics.

* Sophisticated studies indicate that pain is not simply the perception of a certain kind of stimulus but rather a *reaction* to the perception of a variety of kinds of stimuli or stimulus patterns.

Definitions and Concepts

In the field of pharmacology, the vocabulary that is unique to the discipline is relatively small, and the general vocabulary is that of the biological sciences and chemistry. Nevertheless, there are a few definitions that are important to the proper understanding of pharmacology. It is necessary to differentiate among action, effect, selectivity, dose, potency, and efficacy.

Action vs Effect—The *effect* of a drug is an *alteration of function* of the structure or process upon which the drug acts. It is common to use the term action as a synonym for effect. However, action precedes effect. *Action* is the *alteration of condition* that brings about the effect.

The final effect of a drug may be far removed from its site of action. For example, the diuresis subsequent to the ingestion of ethanol does not result from an action on the kidney but instead from a depression of activity in the supraopticohypophyseal region of the hypothalamus, which regulates the release of antidiuretic hormone from the posterior pituitary gland. The alteration of supraopticohypophyseal function is, of course, also an effect of the drug, as is each subsequent change in the chain of events leading to diuresis. The action of ethanol was exerted only at the initial step, each subsequent effect being then the action to a following step.

Multiple Effects—No known drug is capable of exerting a single effect, although a number are known that appear to have a single mechanism of action. Multiple effects may

derive from a single mechanism of action. For example, the inhibition of acetylcholinesterase by physostigmine will elicit an effect at every site where acetylcholine is produced, is potentially active, and is hydrolyzed by cholinesterase. Thus physostigmine elicits a constellation of effects.

A drug can also cause multiple effects at several different sites by a single action at only one site, providing that the function initially altered at the site of action ramifies to control other functions at distant sites. Thus a drug that suppresses steroid synthesis in the liver may not only lower serum cholesterol, impair nerve myelination and function, and alter the condition of the skin (as a consequence of cholesterol deficiency) but also may affect digestive functions (because of a deficiency in bile acids) and alter adrenocortical and sexual hormonal balance.

Although a single action can give rise to multiple effects, most drugs exert multiple actions. The various actions may be related, as, for example, the sympathomimetic effects of metaraminol that accrue to its structural similarity to norepinephrine and its ability partially to suppress sympathetic responses because it occupies the catecholamine storage pools in lieu of norepinephrine; or the actions may be unrelated, as with the actions of morphine to interfere with the release of acetylcholine from certain autonomic nerves, to block some actions of 5-hydroxytryptamine (serotonin); and to release histamine. Many drugs bring about immunologic (allergic or hypersensitivity) responses that bear no relation to the other pharmacodynamic actions of the drug.

Selectivity—Despite the potential most drugs have for eliciting multiple effects, one effect is generally more readily elicitable than another. This differential responsiveness is called *selectivity*. It is usually considered to be a property of the drug, but it is also a property of the constitution and biodynamics of the recipient subject or patient.

Selectivity may come about in several ways. The subcellular structure (receptor) with which a drug combines to initiate one response may have a higher affinity for the drug than that for some other action; atropine, for example, has a much higher affinity for muscarinic receptors (page 876) that subserve the function of sweating than it does for the nicotinic receptors (page 876) that subserve voluntary neuromuscular transmission, so that suppression of sweating can be achieved with only a tiny fraction of the dose necessary to cause paralysis of the skeletal muscles. A drug may be distributed unevenly, so that it reaches a higher concentration at one site than generally throughout the tissues; chloroquine is much more effective against hepatic than intestinal (colonic) amebiasis because it reaches a many times higher concentration in the liver than in the wall of the colon. An affected function may be much more critical to or have less reserve in one organ than in another, so that a drug will be predisposed to elicit an effect at the more critical site; some inhibitors of dopa decarboxylase (which is also 5-hydroxytryptophan decarboxylase) depress the synthesis of histamine more than that of either norepinephrine or 5-hydroxytryptamine (serotonin), even though histidine decarboxylase is less sensitive to the drug, simply because histidine decarboxylase is the only step and hence is rate-limiting in the biosynthesis of histamine. Dopa decarboxylase is not rate-limiting in the synthesis of either norepinephrine or 5-hydroxytryptamine until the enzyme is nearly completely inhibited. Another example of the determination of selectivity by the critical balance of the affected function is that of the mercurial diuretic drugs. An inhibition of only 1% in the tubular resorption of glomerular filtrate will usually double urine flow, since 99% of the glomerular filtrate is normally resorbed; aside from the question of the possible concentration of diuretics in the urine, a drug-induced reduction of 1% in sulfhydryl enzyme activity in tissues other than the kidney is not usually accompanied by an observable change in function. Selectivity also can be

determined by the pattern of distribution of destructive or activating enzymes among the tissues and by other factors.

Dose—Even the uninitiated person knows that the *dose* of a drug is the amount administered. However, the appropriate dose of a drug is not some unvarying quantity, a fact sometimes overlooked by pharmacists, official committees, and physicians, and the practice of pharmacy is entrapped in a system of fixed-dose formulations, so that fine adjustments in dosage are often difficult to achieve. Fortunately, there is usually a rather wide latitude allowable in dosages. It is obvious that the size of the recipient individual should have a bearing upon the dose, and the physician may elect to administer the drug on a body-weight basis rather than as a fixed dose. Usually, however, a fixed dose is given to all adults, unless the adult is exceptionally large or small. The dose for infants and children is often determined by one of several formulas which take into account age or weight, depending on the age group of the child and the type of action exerted by the drug. Infants are relatively more sensitive to many drugs, often because enzyme systems which destroy the drugs may not be fully developed in the infant.

The nutritional condition of the patient, the mental outlook, the presence of pain or discomfort, the severity of the condition being treated, the presence of secondary disease or pathology, genetic, and many other factors affect the dose of a drug necessary to achieve a given therapeutic response or to cause an untoward effect (Chapter 69). Even two apparently well-matched normal persons may require widely different doses for the same intensity of effect. Furthermore, a drug is not always employed for the same effect and hence not in the same dose. For example, the dose of a progestin necessary for an oral contraceptive effect is considerably different from that necessary to prevent spontaneous abortion, and a dose of an estrogen for the treatment of the menopause is much too small for the treatment of prostatic carcinoma.

From the above it is evident that the wise physician knows that *the dose of a drug is "enough"* (ie, no rigid quantity but rather that which is necessary and can be tolerated) and individualizes his regimen accordingly. The wise pharmacist will also appreciate this dictum and recognize that official or manufacturer's recommended doses are sometimes quite narrowly defined and may be very wide of the mark. They should serve only as a useful guide rather than as an imperative.

Potency and Efficacy—The *potency* of a drug is the reciprocal of dose. Thus it will have the units of persons/unit weight of drug or body weight/unit weight of drug, etc. Potency generally has little utility other than to provide a means of comparing the relative activities of drugs in a series, in which case *relative potency*, relative to some prototype member of the series, is a parameter commonly used among pharmacologists and in the pharmaceutical industry.

Whether a given drug is more potent than another has little bearing on its clinical usefulness, provided that the potency is not so low that the size of the dose is physically unmanageable or the cost of treatment is higher than with an equivalent drug. If a drug is less potent but more selective, then it is the one to be preferred. Promotional arguments in favor of a more potent drug are thus irrelevant to the important considerations that should govern the choice of a drug. However, it sometimes occurs that drugs of the same class differ in the maximum intensity of effect; that is, some drugs of the class may be less efficacious than others, irrespective of how large a dose is used.

Efficacy connotes the property of a drug to achieve the desired response, and *maximum efficacy* denotes the maximum achievable effect. Even huge doses of codeine often cannot achieve the relief from severe pain that relatively small doses of morphine can; thus codeine is said to have a lower

maximum efficacy than morphine. Efficacy is one of the primary determinants of the choice of a drug.

Dose-Effect Relationships

The importance of knowing how changes in the intensity of response to a drug vary with the dose is virtually self-evident. Both the physician, who prescribes or administers a drug, and the manufacturer, who must package the drug in appropriate dose sizes, must translate such knowledge into everyday practice. Theoretical or molecular pharmacologists also study such relationships in inquiries into mechanism of action and receptor theory (see page 718). It is necessary to define two types of relationship: (1) the dose-intensity relationship—ie, the manner in which the intensity of effect in the individual recipient relates to dose—and (2) dose-frequency relationship—ie, the manner in which the number of responders among a population of recipients relates to dose.

Dose-Intensity of Effect Relationships—Whether the intensity of effect is determined *in vivo* (eg, the blood-pressure response to epinephrine in the human patient) or *in vitro* (eg, the response of the isolated guinea pig ileum to histamine), the dose-intensity of effect (often called dose-effect) curve usually has a characteristic shape, namely a curve that closely resembles one quadrant of a rectangular hyperbola.

In the dose-intensity curve depicted in Fig 37-2, the curve appears to intercept the x axis at 0 only because the lower doses are quite small on the scale of the abscissa, the smallest dose being $1.5 \times 10^{-3} \mu\text{g}$. Actually, the x intercept has a positive value, since a finite dose of drug is required to bring about a response, this lowest effective dose being known as the *threshold dose*. Statistics and chemical kinetics predict that the curve should approach the y axis asymptotically. However, if the intensity of the measured variable does not start from zero, the curve may possibly have a positive y intercept (or negative x intercept), especially if the ongoing basal activity before the drug is given is closely related to that induced by the drug.

In practice, instead of an asymptote to the y axis, dose-intensity curves nearly always show an upward concave foot at the origin of the curve, so that the curve has a lopsided sigmoid shape. At high doses the curve approaches an asymptote which is parallel to the x axis, and the value of the asymptote establishes the maximum possible response to the drug, or *maximum efficacy*. However, experimental data in




Fig 37-2. The relationship of the intensity of the blood-pressure response of the cat to the intravenous dose of levarterenol.

the regions of the asymptotes are generally too erratic to permit an exact definition of the curve at the very low and very high doses. The example shown represents an unusually good set of data.

Because the dose range may be 100 or 1000 fold from the lowest to the highest dose, it has become the practice to plot dose-intensity curves on a logarithmic scale of abscissa; ie, to plot the log of dose vs the intensity of effect. Fig 37-3 is such a semilogarithmic plot of the same data as in Fig 37-2. In the figure the intensity of effect is plotted both in absolute units (at the left) or in relative units, as percent (at the right).

Although no new information is created by a semilogarithmic representation, the curve is stretched out in such a way as to facilitate the inspection of the data; the comparison of results from multiple observations and the testing of different drugs is also rendered easier. In the example shown, the curve is essentially what is called a *sigmoid curve* and is nearly symmetrical about the point which represents an intensity




Fig 37-3. The relationship of the intensity of the blood-pressure response of the cat to the log of the intravenous dose of levarterenol.

equal to 50% of the maximal effect, ie, about the mid-point. The symmetry follows from the rectangular hyperbolic character of the previous Cartesian plot (Fig 37-2). The semilogarithmic plot reveals better the dose-effect relationships in the low-dose range, which are lost in the steep slope of the Cartesian plot. Furthermore, the data about the mid-point are almost a straight line; the nearly linear portion covers approximately 50% of the curve. The slope of the "linear" portion of the curve, or, more correctly, the slope at the point of inflection, has theoretical significance (see *Drug Receptors and Receptor Theory*, page 718).

The upper portion of the curve approaches an asymptote, which is the same as that in the Cartesian plot. If the response system is completely at rest before the drug is administered, the lower portion of the curve should be asymptotic to the x axis. Both asymptotes and the symmetry derive from the law of mass action (see page 719).

Dose-intensity curves often deviate from the ideal configuration illustrated and discussed above. Usually, the deviate curve remains sigmoid but not extended symmetrically about the mid-point of the "linear" segment. Occasionally other shapes occur, sometimes quite bizarre ones. Deviations may derive from multiple actions that converge upon the same final effector system, from varying degrees of metabolic alteration of the drug at different doses, from modulation of the response by feedback systems, from nonlinearity in the relationship between action and effect, or from other causes.

It is frequently necessary to identify the dose which elicits a given intensity of effect. The intensity of effect that is generally designated is the 50% of maximum intensity. The corresponding dose is called the 50% effective dose, or *individual ED50* (see Fig 37-3). The use of the adjective *individual* distinguishes the ED50 based upon the intensity of effect from the median effective dose, also abbreviated ED50, determined from frequency of response data in a population (see *Dose-Frequency Relationships*; this page).

Drugs that elicit the same quality of effect may be graphically compared. In Fig 37-4, five hypothetical drugs are compared. Drugs A, B, C, and E can all achieve the same maximum effect, which suggests that the same effector system may be common to all. D may possibly be working through the same effector system, but there are no *a priori* reasons to think this is so. Only A and B have parallel curves and common slopes. Common slopes are consistent with but in no way prove, the idea that A and B not only act through the same effector system but also by the same mechanism. Although drug-receptor theory (see *Drug Receptors and Receptor Theory*, page 718) requires that the curves of identical mechanism have equal slopes, examples of exceptions are known. Furthermore, mass-law statistics require that all simple drug-receptor interactions generate the same slope; only when slopes depart from this universal slope in accordance with distinctive characteristics of the response system do slopes provide evidence of specific mechanisms.

The relative potency of any drug may be obtained by di-




Fig 37-4. Log dose-intensity of effect curves of five different hypothetical drugs (see text for explanation).

viding the ED50 of the standard or prototype drug by that of the drug in question. Any level of effect other than 50% may be used, but it should be recognized that when the slopes are not parallel, the relative potency depends upon the intensity of effect chosen. Thus the potency of A relative to C (in Fig 37-4) calculated from the ED50 will be smaller than that calculated from the ED25.

The low maximum intensity inducible by D poses even more complications in the determination of relative potency than do the unequal slopes of the other drugs. If its dose-intensity curve is plotted in terms of percent of its own maximum effect, its relative inefficacy is obscured, and the limitations of relative potency at the ED50 level will not be evident. This dilemma simply underscores the fact that drugs can better be compared from their entire dose-intensity curves than from a single derived number like ED50 or relative potency.

Drugs that elicit multiple effects will generate a dose-intensity curve for each effect. Even though the various effects may be qualitatively different, the several curves may be plotted together on a common scale of abscissa, and the intensity may be expressed in terms of percent of maximum effect; thus all curves can share a common scale of ordinates in addition to common abscissa. Separate scales of ordinates could be employed, but would make it harder to compare data.

The selectivity of a drug can be determined by noting what percent of maximum of one effect can be achieved before a second effect occurs. As with relative potency, selectivity may be expressed in terms of the ratio between the ED50 for one effect to that for another effect, or a ratio at some other intensity of effect. Similarly to relative potency, difficulties follow from nonparallelism. In such instances, selectivity expressed in dose ratios varies from one intensity level to another.

When the dose-intensity curves for a number of subjects are compared, it is found that they vary considerably from individual to individual in many respects: threshold dose, mid-point, maximum intensity, etc, and sometimes even slope. By averaging the intensities of the effect at each dose, an average dose-intensity curve can be constructed.

Average dose-intensity curves enjoy a limited application in comparing drugs. A single line expressing an average response has little value in predicting individual responses unless it is accompanied by some expression of the range of the effect at the various doses. This may be done by indicating the standard error of the response at each dose. Occasionally, a simple scatter diagram is plotted in lieu of an average curve and statistical parameters (see Fig 10-2, page 106). An average dose-intensity curve may also be constructed from a population in which different individuals receive different doses; if sufficiently large populations are employed, the average curves determined by the two methods will approximate each other.

It is obvious that the determination of such average curves from a population sufficiently large to be statistically meaningful requires a great deal of work. Retrospective clinical data occasionally are treated in this way, but prospective studies are infrequently designed in advance to yield average curves. The usual practice in comparing drugs is to employ a quantal (all-or-none) end point and to plot the frequency or cumulative frequency of response over the dose range, as discussed below.

Dose-Frequency of Response Relationships—When an end point is truly all-or-none, such as death, it is an easy matter to plot the number of responding individuals (eg, dead subjects) at each dose of drug or intoxicant. Many other responses that vary in intensity can be treated as all-or-none if simply the presence or absence of a response (eg, cough or no cough, convulsion or no convulsion, etc) is recorded.




Fig 37-5. The relationship of the number of responders in a population of mice to the dose of pentylentetrazol (courtesy, Drs DG McQuarry and EG Fingl, University of Utah).

without regard to the intensity of the response when it occurs.

When the response grades from the basal or control state in a less abrupt manner (eg, tachycardia, miosis, rate of gastric secretion, etc) it may be necessary to designate arbitrarily some particular intensity of effect as the end point. If the end point is taken as an increase in heart rate of 20 beats/min, then all individuals whose tachycardia is less than 20/min would be recorded as nonresponders, while all those with 20 or above would be recorded as responders. When the percent of responders in the population is plotted against the dose, a characteristic dose-response curve, more properly called a *dose-cumulative frequency* or *dose-percent* curve, is generated. Such a curve is, in fact, a cumulative frequency-distribution curve, the percent of responders at a given dose being the frequency of response.

Dose-cumulative frequency curves are generally of the same geometric shape as dose-intensity curves (namely, sigmoid) when frequency is plotted against log dose (see Fig 37-5). The tendency of the cumulated frequency of response (ie, percent) to be linearly proportional to the log of the dose in the middle of the dose range is called the *Weber-Fechner law*, although it is not invariable, as a true natural law should be. In many instances, the cumulative frequency is simply proportional to dose rather than log dose. The Weber-Fechner law applies to either dose-intensity or dose-cumulative frequency data. The similarity between dose-frequency and dose-intensity curves may be more than fortuitous, since the intensity of response will usually have an approximately linear relationship to the percent of responding units (smooth muscle cells, nerve fibers, etc) and hence is also a type of cumulative frequency of response. These are the same kind of statistics that govern the law of mass action.

If only the increase in the number of responders with each new dose is plotted, instead of the cumulative percent of responders, a bell-shaped curve is obtained. This curve is the

first derivative of the dose-cumulative frequency curve and is a *frequency-distribution* curve (see Chapter 10). The distribution will be symmetrical—ie, *normal* or Gaussian (see Fig 10-6, page 109)—only if the dose-cumulative frequency curve is symmetrically hyperbolic. Because most dose-cumulative frequency curves are more nearly symmetrical when plotted semilogarithmically (ie, as log dose), dose-cumulative frequency curves are usually *log-normal*.

Since the dose-intensity and dose-cumulative frequency curves are basically similar in shape, it follows that the curves have similar defining characteristics, such as ED50, maximum effect (maximum efficacy), and slope. In dose-cumulative frequency data, the ED50 (*median effective dose*) is the dose to which 50% of the population responds (see Fig 37-5). If the frequency distribution is normal, the ED50 is both the arithmetic mean and median dose and is represented by the mid-point on the curve; if the distribution is log-normal, the ED50 is the median dose but not the arithmetic mean dose. The efficacy is the cumulative frequency summed over all doses; it is usually but not always 100%. The slope is characteristic of both the drug and test population. Even two drugs of identical mechanism may give rise to different slopes in dose-percent curves, whereas in dose-intensity curves the slopes are the same.

Statistical parameters (such as standard deviation)—in addition to ED50, maximum cumulative frequency (efficacy), the slope—characterize dose-cumulative frequency relationships (see Chapter 10).

There are several formulations for dose-cumulative frequency curves, some of which are employed only to define the linear segment of a curve and to determine the statistical parameters of this segment. For the statistical treatment of dose-frequency data, see Chapter 10. One simple mathematical expression of the entire log-symmetrical sigmoid curve is

$$\log \text{dose} = K + f \log \left(\frac{\% \text{ response}}{100\% - \text{response}} \right) \quad (1)$$

where percent response may be either the percent of maximum intensity or the percent of a population responding. The equation is thus basically the same for both log normal dose-intensity and log normal dose-percent relationships. K is a constant that is characteristic of the mid-point of the curve, or ED50, and $1/f$ is characteristically related to the slope of the linear segment, which, in turn is closely related to the standard deviation of the derivative log normal frequency distribution curve.

The comparison of dose-percent relationships among drugs is subject to the pitfalls indicated for dose-intensity comparisons (see page 715); namely, that when the slopes of the curves are not the same (ie, the dose-percent curves are not parallel); it is necessary to state at which level of response a potency ratio is calculated. As with dose-intensity data, potencies are generally calculated from the ED50, but potency ratios may be calculated for any arbitrary percent response. The expression of selectivity is likewise subject to similar qualifications, inasmuch as the dose-percent curves for the several effects are usually nonparallel.

The term *therapeutic index* is used to designate a quantitative statement of the selectivity of a drug when a therapeutic and an untoward effect are being compared. If the untoward effect is designated as T (for toxic) and the therapeutic effect as E , the therapeutic index may be defined as TD50/ED50 or a similar ratio at some other arbitrary levels of response. The TD and the ED are not required to express the same percent of response; some clinicians use the ratio TD1/ED99 or TD5/ED95, based on the rationale that if the untoward effect is serious, it is important to use a most severe therapeutic index in passing judgment upon the drug. Unfortunately,

therapeutic indices are known in man for only a few drugs.

There will be a different therapeutic index for each untoward effect that a drug may elicit, and, if there is more than one therapeutic effect, a family of therapeutic indices for each therapeutic effect. However, in clinical practice, it is customary to distinguish among the various toxicities by indicating the percent incidence of a given side effect.

Variations in Response and Responsiveness—From the above discussion of dose–frequency relationships and Chapter 10, it is obvious that in a normal population of persons there may be quite a large difference in the dose required to elicit a given response in the least-responsive member of the population and that to elicit the response in the most-responsive member. The difference will ordinarily be a function of the slope of the dose–percent curve, or, in statistical terms, of the standard deviation. If the standard deviation is large, the extremes of responsiveness of responders are likewise large.

In a normal population 95.46% of the population responds to doses within two standard deviations from the ED₅₀ and 99.73% within three standard deviations. In log normal populations the same distribution applies when standard deviation is expressed as log dose.

In the population represented in Fig 37-5, 2.25% of the population (two standard deviations from the median) would require a dose more than 1.4 times the ED₅₀; an equally small percent would respond to 0.7 the ED₅₀. The physician who is unfamiliar with statistics is apt to consider the 2.25% at either extreme as abnormal reactors. The statistician will argue that these 4.5% are within the normal population and that only those who respond well outside of the normal population, at least three standard deviations from the median, deserve to be called abnormal.

Irrespective of whether the physician's or the statistician's criteria of abnormality obtain, the term *hyporeactive* applies to those individuals who require abnormally high doses and *hyperreactive* to those who require abnormally low doses. The terms *hyporesponsive* and *hyperresponsive* may also be used. It is incorrect to use the terms *hyposensitive* and *hypersensitive* in this context; *hypersensitivity* denotes an allergic response to a drug and should not be used to refer to hyperreactivity. The term *supersensitivity* correctly applies to hyperreactivity that results from denervation of the effector organ; it is often more definitively called denervation supersensitivity. Sometimes hyporeactivity is the result of an immunochemical deactivation of the drug, or *immunity*. Hyporeactivity should be distinguished from an increased

dose requirement that results from a severe pathological condition. Severe pain requires large doses of analgesics, but the patient is not a hyporeactor; what has changed is the baseline from which the end-point quantum is measured. The responsiveness of a patient to certain drugs sometimes may be determined by the history of previous exposure to appropriate drugs.

Tolerance is a diminution in responsiveness as use of the drug continues. The consequence of tolerance is an increase in the dose requirement. It may be due to an increase in the rate of elimination of drug, as discussed elsewhere in this chapter, to reflex or other compensatory homeostatic adjustments, to a decrease in the number of receptors or in the number of enzyme molecules or other coupling proteins in the effector sequence, to exhaustion of the effector system or depletion of mediators, to the development of immunity, or to other mechanisms. Tolerance may be gradual, requiring many doses and days to months to develop, or acute, requiring only the first or a few doses and only minutes to hours to develop. Acute tolerance is called *tachyphylaxis*.

Drug resistance is the decrease in responsiveness of microorganisms, neoplasms, or pests to chemotherapeutic agents, antineoplastics, or pesticides, respectively. It is not tolerance in the sense that the sensitivity of the individual microorganism or cancer cell decreases; rather it is the survival of normally unresponsive cells which then pass the genetic factors of resistance on to their progeny.

Patients who fail to respond to a drug are called *refractory*. Refractoriness may result from tolerance or resistance, but it may also result from the progression of pathological states that negate the response or render the response incapable of surmounting an overwhelming pathology. Rarely, it may result from a poorly developed receptor or response system.

Sometimes a drug evokes an unusual response that is *qualitatively* different from the expected response. Such an unexpected response is called a *meta-reaction*. A not uncommon meta-reaction is a central nervous stimulant rather than depressant effect of phenobarbital, especially in women. Certain pathological states and pain sometimes favor meta-reactivity. Responses that are different in infants or the aged than in young and middle-aged people are not meta-reactions if the response is usual in the age group. The term *idiosyncrasy* also denotes meta-reactivity, but the word has been so abused that it is recommended that it be dropped. Although hypersensitivity may cause unusual effects, it is not included in meta-reactivity.

Drug Receptors and Receptor Theory

Most drugs act by combining with some key substance in the biological milieu that has an important regulatory function in the target organ or tissue. This biological partner of the drug goes by the name of *receptive substance* or *drug receptor*. The receptive substance is mostly considered to be a cellular constituent, although in a few instances it may be extracellular, as the cholinesterases are, in part. The receptive substance is thought of as having a special chemical affinity and structural requirements for the drug. Drugs such as emollients, which have a physical rather than chemical basis for their action, obviously do not act upon receptors. Drugs, such as demulcents and astringents, which act in a nonselective or nonspecific chemical way are also not considered to act upon receptors, since the candidate receptors have neither sharp chemical nor biological definition. Even antacids, which react with the extremely well-defined hydronium ion, cannot be said to have a receptor, since the reactive proton has no permanent biological residence.

Because of early preoccupation with physical theories of action and the classical and illogical dichotomy of chemical and physical molecular interaction, there is a reluctance to admit receptors for drugs such as local anesthetics, general anesthetics, certain electrolytes, etc, which are not generally accepted to combine with cellular or organelle membrane constituents. The word receptor is used often inconsistently and intuitively. However, the term is a legitimate symbol for that biological structure with which a drug interacts to initiate a response. The fact that we are ignorant of the identities of most receptors does not detract from but rather increases the importance of the term and general concept.

Once a receptor is identified, it is frequently no longer thought of as a receptor, although such identification may afford the basis of profound advances in receptor theory. Since the effects of anticholinesterases are only indirectly derived from inhibition of cholinesterase and no drugs are known that stimulate the enzyme, it may be argued that

not a receptor. Nevertheless, it is probable that a number of drugs ultimately will be revealed to act indirectly through the inhibition of such modulator enzymes, and it is important for the theoretician to develop models based upon such indirect interrelations.

Enzymes, of course, readily suggest themselves as candidates for receptors. However, there is more to cellular function than enzymes. Receptors may be membrane or intracellular constituents that govern the spatial orientation of enzymes, compartmentalization of the cytoplasm, contractile or compliant properties of subcellular structures, or permeability and electrical properties of membranes. For nearly every cellular constituent there can be imagined a possible way for a drug to affect its function; therefore, few cellular constituents can be dismissed *a priori* as possible receptors. The nicotinic receptor appears to be a membrane constituent that regulates the "gates" of certain ionic channels through the membrane. The beta adrenoreceptor appears to be a membrane constituent which modulates the closely proximate enzyme, adenylate cyclase.

Occupation and Other Theories

Drug-receptor interactions are governed by the law of mass action, a concept initiated by Langley in 1878. However, most chemical applications of mass law are concerned with the rate at which reagents disappear or products are formed, whereas receptor theory usually concerns itself with the fraction of the receptors combined with a drug, similar to theories of adsorption. The usual concept is that only when the receptor is actually occupied by the drug is its function transformed in such a way as to elicit a response. This concept has become known as the *occupation theory*. The earliest clear statement of its assumptions and formulations is often credited to Clark in 1926, but both Langley and Hill made important contributions to the theory in the first two decades of this century.

In all receptor theories, the terms agonist, partial agonist, and antagonist are employed. An *agonist* is a drug that combines with a receptor to initiate a response.

In the classical occupation theory, two attributes of the drug are required: (1) *affinity*, a measure of the equilibrium constant of the drug-receptor interaction and (2) *intrinsic activity*, or *efficacy* (not to be confused with efficacy as maximum effect), a measure of the ability of the drug to induce a positive change in the function of the receptor.

A *partial agonist* is a drug that can elicit some but not a maximal effect and which antagonizes an agonist. In the occupation theory it would be a drug with a favorable affinity but a low intrinsic activity.

A *competitive antagonist* is a drug that occupies a significant proportion of the receptors and thereby preempts them from reacting maximally with an agonist. In the occupation theory the prerequisite property is affinity without intrinsic activity.

A *noncompetitive antagonist* may react with the receptor in such a way as not to prevent agonist-receptor combination but to prevent the combination from initiating a response, or it may act to inhibit some subsequent event in the chain of action-effect-action-effect that leads to the final overt response.

The mathematical formulation of the receptor theories derives directly from the law of mass action and chemical kinetics. Certain assumptions are required to simplify calculations. The key assumption is that the intensity of effect is a direct linear function of the proportion of receptors occupied. The correctness of this assumption is most improbable on the basis of theoretical considerations, but empirically it appears to be a close enough approximation to be useful. A second assumption upon which formulations are based is that

the drug-receptor interaction is at equilibrium. Another common assumption is that the number of molecules of receptor is negligibly small compared to that of the drug. This assumption is undoubtedly true in most instances, and departures from this situation greatly complicate the mathematical expression of drug-receptor interactions.

The first clearly stated mathematical formulation of drug-receptor kinetics was that of Clark.¹ In his equation,

$$Kx^n = \frac{y}{100 - y} \quad (2)$$

where K is the affinity constant, x is the concentration of drug, n is the molecularity of the reaction, and y is the percent of maximum response. Clark assumed that y was a linear function of the percent of receptors occupied by the drug, so that y could also symbolize the percent of receptors occupied. When the equation is rearranged to solve for y ,

$$y = \frac{100Kx^n}{1 + Kx^n} \quad (3)$$

A Cartesian plot of this equation is identical in form to that shown in Fig 37-2. When y is plotted against $\log x$ instead of x , the usual sigmoid curve is obtained. Thus it may be seen that the dose-intensity curve derives from mass action equilibrium kinetics, which in turn derive from the statistical nature of molecular interaction. The fact that dose-intensity and dose-percent curves have the same shape shows that they both involve the same kind of statistics.

If Eq 2 is put into log form,

$$\log K + n \log x = \log \frac{y}{100 - y} \quad (4)$$

a plot of $\log y/100 - y$ against $\log x$ will then yield a straight line with a slope of n ; n is theoretically the number of molecules of drug which react with each molecule of receptor. At present, there are no known examples in which more than one molecule of agonist combines with a single receptor, hence n should be equal to 1, universally. Nevertheless, n often deviates from 1; deviations occur because of cooperative interactions among receptors (*cooperativity*), *spare receptors* (see below), amplifications in the response system ("cascades"), receptor coupling to more than one sequence (eg, to both adenylate cyclase and calcium channels, etc), and other reasons. In these departures from $n = 1$, the slope becomes a characteristic of the mechanism of action and response system.

The probability that a molecule of drug will react with a receptor is a function of the concentration of both drug and receptor. The concentration of receptor molecules cannot be manipulated like the concentration of a drug. But as each molecule of drug combines with a receptor, the population of free receptors is diminished accordingly. If the drug is a competitive antagonist, it will diminish the probability of an agonist-receptor combination in direct proportion to the percent of receptor molecules preempted by the antagonist. Consequently, the intensity of effect will be diminished. However, the probability of agonist-receptor interaction can be increased by increasing the concentration of agonist, and the intensity of effect can be restored by appropriately larger doses of agonist. Addition of more antagonist will again diminish the response, which can, again, be overcome or *surmounted* by more agonist.

Clark showed empirically and by theory that as long as the ratio of antagonist to agonist was constant, the concentration of the competitive drugs could be varied over an enormous range without changing the magnitude of the response (see Fig 37-6). Since the presence of competitive antagonist only diminishes the probability of agonist-receptor combination at a given concentration of agonist and does not alter the molecularity of the reaction, it also follows that the effect of




Fig 37-6. Direct proportionality of the dose of agonist (acetylcholine) to the dose of antagonist (atropine) necessary to cause a constant degree of inhibition (50%) of the response of the frog heart (courtesy, adaptation, Clark¹).

the competitive antagonist is to shift the dose-intensity curve to the right in proportion to the amount of antagonist present; neither shape nor slope of the curve is changed (see Fig 37-7). Both Figs 37-6 and 37-7 are from Clark's original paper on competitive antagonism.¹

Many refinements of the Clark formula have been made, but they will not be treated here; details and citations of relevant literature can be found in references 2-6 and among various works on receptors cited in the Bibliography. Several refinements are introduced to facilitate studies of competitive inhibition. The introduction of the concept of intrinsic activity³ and efficacy⁴ required appropriate changes in mathematical treatment.

Another important concept has been added to the occupation theory, namely the concept of *spare receptors*. Clark assumed the maximal response to occur only when the receptors were completely occupied, which does not account for the possibility that the maximum response might be limited by some step in the action-effect sequence subsequent to receptor occupation. Work with isotopically labelled agonists and antagonists and with dose-effect kinetics has shown that the maximal effect is sometimes achieved when only a small fraction of the receptors are yet occupied. The mathematical treatment of this phenomenon has enabled theorists to explain several puzzling observations that previously appeared to contradict drug-receptor theory.

The classical occupation theory fails to explain several phenomena satisfactorily, and it is unable to generate a real-




Fig 37-7. Effect of an antagonist to shift the log dose-intensity curve to the right without altering the slope. The effector is the isolated heart. I: no atropine; II: atropine, $10^{-8}M$; III: 10^{-7} ; IV: 10^{-6} ; V: 10^{-5} ; VI: 10^{-4} ; VII: 10^{-3} . Y: % of maximum intensity of response; the function $\log y/(100-y)$ converts the log dose-intensity relationship to a straight line (courtesy, adaptation, Clark¹).

istic model of intrinsic activity and partial agonism. A rate theory, in which the intensity of response is proportional to the rate of drug-receptor interaction instead of occupation, was proposed to explain some of the phenomena that occupation theory could not, but the rate theory was unable to provide a realistic mechanistic model of response generation, and it had other serious limitations as well.

The phenomena that neither the classical occupation nor rate theory could explain can be explained by various theories in which the receptor can exist in at least two conformational states, one of which is the active one; the drug can react with one or more conformers. In a *two-state model*⁷



where R is the inactive and R* is the active conformer. The agonist combines mainly with R*, the partial agonist can combine with both R and R*, and the antagonist can combine with R, the equilibrium being shifted according to the extent of occupation of R and R*. Other variations of occupation theory treat the receptor as an aggregate of subunits which interact cooperatively (see Ref 8).

The Nature of Receptor Groups and Models of Receptors

A *receptor group* is that portion of the receptor molecule with which an agonist acts and which is vital to the function of the receptor. Studies of receptor group composition and configuration are too complex for the purposes of this text; consequently, only a brief sketch will be made here to orient casually the reader to the nature of the approach.

From the chemical configuration and reactivity of agonists and antagonists, certain deductions can be made about the structure of a receptor group. For example, all highly active agonists of muscarinic receptors are cations at physiological pH. This suggests that the receptor group contains an anionic group and that the force of attraction is electrostatic, at least in part, which agrees with thermodynamic data. That van der Waals forces (especially Heitler-London fluctuation forces) may also make an important contribution to binding is suggested by the requirement for *N*-methyl groups and by the low but definite activity of the nonionizable quaternary carbon analogue of acetylcholine, 3,3-dimethylbutyl acetate. This establishes a requirement for an auxiliary structure close to the anionic site. Studies of the contribution to activity of ester and carbonyl oxygen among analogues of acetylcholine, of intramolecular distances, and of the stereospecificity of various isomers and conformers have indicated a partial cationic (proton donor) site between 2.5 and 4 Å and a region of high electronic density (electron donor) between 5 and 7 Å from the anionic site. This is similar to the way in which the active site of acetylcholinesterase was mapped (see text, page 442, and Fig 27-4).

The structure-activity relationships among competitive inhibitors must also be consistent with any model of a receptor. However, binding sites additional to the receptor group can be involved, and results are frequently more difficult to interpret than those with agonists. Nevertheless, studies with antagonists have made a substantial contribution to receptor group analysis. There is considerable interest in antagonists that combine irreversibly with the receptor, since such drugs offer a way of marking (affinity labeling) the receptor for isolation and for identification of the receptor group.

Since receptors for autonomic agonists appear to be embedded in the cell membrane, they have been difficult to isolate without inactivation. Several laboratories have succeeded in isolating proteins, the chemical properties of which are consistent with those expected of the nicotinic receptor. Receptors for steroid hormones have been easier to isolate.

and some have been relatively well characterized. The student interested in further details of drug-receptor interactions and the nature of receptors should peruse Refs 9-17 and the various works on receptors cited in the bibliography.

Up and Down Regulation—In many receptor-effector systems, if there is a paucity of agonist, the system will respond by increasing the responsiveness, by increasing the number of receptors on the effector membrane or number of coupling proteins or enzymes in the effector system. This is known as *up-regulation*. In adrenergic systems, sympathetic denervation has been shown to increase the number of post-synaptic β -adrenoreceptors at some junctions and the availability of nucleotide-binding protein units and/or adenylate cyclase molecules at others. Hyperthyroid activity also in-

creases the number of β -adrenoreceptors in heart muscle, which explains the excessive heart rate. Prolonged blockade of receptors by antagonists may also cause up-regulation. The abrupt discontinuation of treatment, such that drug levels fall faster than re-regulation, may be followed by excessive activity, as, for example, pernicious tachycardia and angina pectoris from abrupt withdrawal of propranolol.

Excessive agonism will lead to a decrease in the number of receptors or in stimulus-response coupling. This one cause of tachyphylaxis or tolerance, such as occurs to the bronchodilator effects of β -adrenoreceptor agonists. Abrupt withdrawal may result in poor residual function or in rebound effects, depending upon the type of effect caused by the agonist.

Mechanism of Drug Action

Any metabolic or physiological function provides a potential mechanism of action of a drug. The term *mechanism of action* has been employed in a number of ways. In the past it was often the habit to confuse the site or locus of action with the mechanism of action. For example, the mechanism of the hypotensive action of tetraethylammonium ion was originally described as that of ganglionic blockade, which did nothing more than identify the anatomical structure upon which the drug acted. In a general sense, this was a partial elucidation of the mechanism of action, if mechanism is used in the mechanical sense of the entire linkage between the input and output of a machine. However, there has been a gradual narrowing of the definition of mechanism of action to be restricted to only the first event in the action-effect sequence, that is, only to the alteration of receptor function by the drug. In this sense the mechanism of action of tetraethylammonium is more appropriately defined as that of competition with acetylcholine for nicotine cholinergic receptors on the post-synaptic ganglion cell membrane, even though the alteration in receptor function is not defined. The ultimate mechanism of action is known for only a few drugs.

It is customary to speak of a drug as a stimulant or a depressant, of the action as being excitatory or inhibitory, etc. Such terms describe only the effect and not the action, and they have no bearing upon whether the drug augments receptor function or diminishes it. In biological systems positive and negative modulation and feedback occur at every level, the organ as well as the subcellular. Thus an agonist to a negative modulator may be able to bring about the same effect as an antagonist to a positive modulator. It is possible for an antagonist or inhibitor to elicit an excitatory effect. An example is the convulsant action of strychnine, which results from its antagonism of glycine, an important mediator of postsynaptic inhibition in the central nervous system. Conversely, it is possible for an agonist to elicit an inhibitory effect. An example is the reflex bradycardia that results from the stimulant action of veratrum alkaloids on chemoreceptors in the left ventricle.

Because of the central role *enzymes play* in cellular function, it is not surprising that thinking about the mechanism of action of drugs has focused largely upon enzymes. Agonist drugs conceivably could serve as substrates, cofactors, or activators. At the present time, no drug is definitely known to exert its action as a substrate or as a cofactor, exclusive of vitamins and known nutrients. However, at least three classes of drugs are known and several are suspected to work through the activation of enzymes.

The most notable example of enzyme activation is that of epinephrine and similar β -adrenoreceptor agonists, which activate adenylyl cyclase to increase the production of 3',5'-cyclic adenylic acid (cyclic AMP; CAMP). The metabolic and cardiac effects of catecholamines are attributable in part to

the increment in cyclic AMP. One modulator of adenylyl cyclase is the β -adrenergic receptor. The β -adrenoreceptor is coupled to adenylyl cyclase through a regulatory protein that binds GDP and GTP. When GDP is present, the agonist-receptor complex is associated with the regulatory protein. GTP causes transfer of the regulatory protein to adenylyl cyclase and dissociation of the β -adrenoreceptor. Glucagon also owes its hyperglycemic action to activation of hepatic adenylyl cyclase. There is thus the interesting phenomenon of one enzyme, adenylyl cyclase, being activated by two chemically unrelated drugs. Since β -adrenergic blocking agents do not antagonize glucagon, it is obvious that glucagon works upon a different receptor than does epinephrine.

CAMP activates protein kinases that increase the activity of phosphorylase, actomyosin, the sequestration of calcium by the sarcoplasmic reticulum, and calcium channels. Thus a brief activation of the β -adrenoreceptor sets in motion a cascade of events that greatly amplify the signal.

Other important enzymes coupled to receptors are guanylate cyclase and phospholipases A and C, which are involved with membrane fluidity and calcium channels, respectively.

Many drugs are inhibitors of enzymes. When the drug is a *competitive inhibitor* of a natural endogenous substrate of the enzyme, it is called an *antimetabolite* (see also page 442). Examples of antimetabolites are sulfonamides, which compete with para-aminobenzoic acid and thus interfere with its incorporation into dihydrofolic acid, and methotrexate, which competes with folic acid for dihydrofolate reductase and thus interferes with the formation of folic acid. It might seem that anticholinesterases are also antimetabolites, although they are never placed into that classification. The reason is that the products of cholinesterase-acetylcholine interaction do not subserve important metabolic functions, as do folic and folic acids, so that the organism is not deprived of an important metabolite by the action of the cholinesterase inhibitors.

Some drugs are competitive inhibitors of enzyme systems whose natural function appears not to produce useful metabolites but to rid the body of foreign substances. Inhibitors of the hepatic microsomes and probenecid fall into this category; the hepatic microsomes do perform a few biotransformations on endogenous substrates, but the renal tubular anion transport system does not appear to be required to eliminate any important endogenous substances.

Since neither the hepatic microsomes nor the tubular anion transport system seems to be involved in response systems, inhibitors of these enzyme systems are antagonists without corresponding agonists. Indeed, even natural endogenous substrates of enzymes are rarely considered to be agonists.

Noncompetitive enzyme inhibitors among drugs are also known. Examples are cyanide, fluoride, disulfiram, and cardiac glycosides. When enzyme inhibition is the basis of

positive response—eg, the cholinergic effects of the anticholinesterases or the effects of diazoxide consequent to inhibition of phosphodiesterase—the drug appears to be an agonist. Yet there can be no competitive antagonist to such an inhibitor, since the competitor to the drug is more substrate, to which the effect of the drug is actually attributable.

Acetylcholine increases the permeability of the subsynaptic membrane to cations and the heart muscle membrane to potassium. The mechanism is generally thought to involve a change in conformation of a membrane constituent so that pore size or permeability constant is affected. Other autonomic agonists are also known to alter the permeability to ions, in part through activation of adenylyl cyclase, guanylyl cyclase, phospholipase-c, or other enzymes. Many drugs and toxins, among them local anesthetics, some sedative-hypnotics, general anesthetics, and tetrodotoxin, act through alterations in the structural and physical properties of membranes. To the extent that some of such substances may disperse themselves generally throughout the lipid phase of the membrane rather than to combine with special chemical entities, no definite receptors for such drugs can be said to exist.

The mechanism of action of certain drugs, especially autonomic drugs, is often stated to be *mimicry* of a natural neurohumor or hormone. Thus methacholine mimics acetylcholine as an agonist. This does not define the mechanism of action, unless the mechanism of action of the natural substance is known.

Mimicry usually occurs because of a structural similarity between the natural substance and the mimetic drug. Mimicry in agonist functions is easy to demonstrate, but the site of action may not always be mimicry of the natural agonist at its receptor but rather at its storage site to release the natural agonist.

Examples of mimetics that act by release of the natural mediator are sympathomimetics such as *d*-amphetamine, mephentermine, ephedrine (in part), tyramine, and others, which are now known to act by displacing norepinephrine from storage sites within the adrenergic neuron. Many of such indirectly acting sympathomimetics lack a direct action on the adrenergic receptor, although some, like ephedrine, act both upon the receptor and the storage complex. Another mimetic by a release mechanism is carbachol, which promotes the presynaptic discharge of acetylcholine.

In these examples there is a close structural similarity between the mimetic and the released mediator. In the case of many releasers of histamine (such as tubocurarine, polymyxin, or morphine) no close chemical relationship exists between the releaser and the released. In such instances release has been explained by activation of receptors on the mast-cell membrane which promote exocytosis of the histamine-containing granules, by an influx of calcium, and activation of microtubules, all of which may be involved in moving the granules out of the mast cell.

Structural similarity may also aid mimicry by promoting chemical combination with an enzyme of destruction or some other means of disposition. For example, metaraminol, amphetamine, etc inhibit membrane transport into the neuron and hence inhibit the neuronal recapture of released norepinephrine. Consequently, the extraneuronal concentration of norepinephrine in the nearby region of the receptors does not drop as rapidly as in the absence of the mimetic, and the action of the mediator is sustained.

Some inhibitors of the enzymes of the destruction of mediators are structurally similar enough to the mediator to have some agonist action. This is true of neostigmine, which has a direct stimulant action on nicotinic receptors in addition to its anticholinesterase action. In contrast, the anticholinesterase

terase physostigmine has some antagonist actions on cholinergic receptors and also an effect to interfere with acetylcholine synthesis.

The above multiple actions come about because all the structures that interact with a small molecule mediator (the receptor, synthesizing enzyme, destructive enzyme, storage molecule, membrane transport carrier) must have some common structural features and affinities. A drug that reacts with one of these molecules has a distinct probability of interacting with another.

The recognition of the critical role of ions in the function of membranes, the excitability of cells, and the activity of many enzymes has generated a renewed interest in ions in the mechanism of action of certain drugs. The inorganic ions, some of which are used as drugs, lend themselves automatically to a discussion of ionic mechanisms. The repair of electrolyte deficiencies by replacement therapy warrants no further comment here. Some nonphysiological ions act as imperfect impersonators of physiological ions; lithium partly substitutes for sodium, bromide for chloride and thiocyanate for iodide, and each may owe its pharmacological action, in part, to a sluggish mobility through membrane channels, through which their sister ions normally pass readily when traffic is not impeded by "slowly moving vehicles." Iodide has an effect to increase the penetrance of drugs into caseous and necrotic areas, to aid in the resolution of gummatous lesions, to reduce the viscosity of mucous secretions, and other odd effects; it is thought to do so by increasing the hydration of collagen and mucoproteins by a poorly understood mechanism. The transition and heavy metals have in common the ability to form complexes with a variety of physiologically active substances, particularly the active centers of many enzymes. *Chelation* and other *complexation* are the mechanisms of action of several drugs used to treat heavy metal intoxication, diseases that involve abnormal body burdens or plasma levels of heavy metals, and hypercalcemia. Chelates and chelation are discussed in more detail on pages 187 and 188.

There is much interest in the effects of drugs on ion movements. Cardiac glycosides are known to inhibit an ATPase involved in the membrane transport of sodium and several other substances, which indirectly causes an increase in intracellular calcium content. In part, the mechanisms of action of local anesthetics, quinidine, and various other drugs are also speculated to involve calcium movements. More recently, there has appeared a whole new class of drugs, the calcium channel blockers.

Concomitant with the development of molecular biology was the appreciation that drugs act through *nuclear* and *extranuclear genetic mechanisms*. Nitrogen mustards have long been known to interfere with the replication of DNA. Streptomycin, kanamycin, neomycin, and gentamicin cause misreading by the ribosomes of the code incorporated into messenger RNA; tetracyclines, erythromycin, and chloramphenicol inhibit the synthesis of protein at the ribosomes; and chloroquine, novobiocin, and colchicine inhibit DNA polymerase. Other drugs induce the production of enzymes; aldosterone appears to act by inducing the synthesis of the enzyme, membrane ATPase, necessary to sodium transport. Many drugs induce one or more of the hepatic and extrahepatic cytochrome P-450 enzymes.

A number of drugs have simple mechanisms that do not involve an action at the cellular level. Examples are bulk and saline cathartics, osmotic diuretics, and cholestyramine. Although such drugs usually do not generate much excitement among pharmacologists, they do serve to remind us of the many avenues through which mechanism of action may be expressed. Throughout the various chapters of Part 6 specific mechanisms of action may be mentioned.

Absorption, Distribution, and Excretion

No matter by which route a drug is administered it must pass through several to many biological membranes during the processes of absorption, distribution, biotransformation, and elimination. Since membranes are traversed in all of these events, the subject of this section will begin with a brief description of biological membranes and membrane processes and the relationship of the physicochemical properties of a drug molecule to penetrance and transport.

Structure and Properties of Membranes

The concept that a membrane surrounds each cell arose shortly after the cellular nature of tissue was discovered. The biological and physicochemical properties of cells seemed in accord with this view. In the past, from time to time the actual existence of the membrane has been questioned by brilliant men, and ingenious explanations have been advanced to explain cellular integrity and the osmotic and electrophysiological properties of cells. Microchemical, X-ray diffraction, electron microscopic, nuclear magnetic resonance, electron spin resonance, and other investigations have proved both the existence and nature of the plasma, mitochondrial, nuclear and other cell membranes. The description of the plasma membrane that follows is somewhat oversimplified, but it will suffice to provide a background for an understanding of penetrance into and through membranes.

Structure and Composition—The cell membrane has been described as a "mayonnaise sandwich," in which a bimolecular layer of lipid material is entrained between two parallel monomolecular layers of protein. However, the protein does not make continuous layers, like the bread in a sandwich, but rather is sporadically scattered over the surfaces, like icebergs; like icebergs, much of the protein is below the surface. In Fig 37-8 the lipid layers are represented as a somewhat orderly, closely packed lamellar array of phospholipid molecules associated tail-to-tail, each "tail" being an alkyl chain or steroid group and the "heads" being polar groups, including the glycerate moieties, with their polar ether and carbonyl oxygens and phosphate with attached polar groups. In reality the lamellar portion is probably not so orderly, since its composition is quite complex. Chains of fatty acids of different degrees of saturation and cholesterol cannot array themselves in simple parallel arrangements. Furthermore, the polar heads will assume a number of orientations depending upon the substances and groups involved. Moreover, the lamellar portion is penetrated by large globular proteins, the interior of which, however, like the lipid layers, has a high hydrophobicity, and some fibrous proteins.

The plasma membrane appears to be asymmetrical. The lipid composition varies from cell type to cell type and perhaps from site to site on the same membrane. There are, for example, differences between the membrane of the endoplasmic reticulum and the plasma membrane, even though the membranes are coextensive. Where membranes are double, the inner and outer layers may differ considerably; the inner and outer membranes of mitochondria have been shown to have strikingly different compositions and properties. Some authorities have expressed doubt as to the existence of the protein layers in biological membranes, although the evidence is preponderantly in favor of at least an outer glycoprotein coat. Sugar moieties are also attached to the outer proteins; these sugar moieties are important to cellular and immunological recognition and adhesion and have other functions as well.

The cell membrane appears to be perforated by water-filled pores of various sizes, varying from about 4–10 Å, being predominantly around 7 Å. Probably all major ion channels are

through the large globular proteins that traverse the membrane. Through these pores pass inorganic ions and small organic molecules. Since sodium ions are more hydrated than potassium and chloride ions, they are larger and do not pass as freely through the pores as potassium and chloride. The vascular endothelium appears to have pores at least as large as 40 Å, but these seem to be interstitial passages rather than transmembrane pores. Lipid molecules small enough to pass through the pores may do so, but they have a higher probability of entering into the lipid layer, from where they will equilibrate chemically with the interior of the cell. From work on monolayers, some workers contend that it is not necessary to postulate pores to explain the permeability to water and small water-soluble molecules.

Stratum Corneum—Although the stratum corneum is not a membrane in the same sense as a cell membrane, it offers a barrier to diffusion, which is of significance in the topical application of drugs. The stratum corneum consists of several layers of dead keratinized cutaneous epithelial cells enmeshed in a matrix of keratin fibers and bound together with cementing desmosomes and penetrating tonofibrils of keratin. Varying amounts of lipids and fatty acids from dying cells, sebum, and sweat are contained among the dead squamous cells. Immediately beneath the layer of dead cells and above the viable epidermal epithelial cells is a layer of keratohyaline granules and various water-soluble substances, such as alpha-amino acids, purines, monosaccharides, and urea.

Both the upper and lower layers of the stratum corneum are involved in the cutaneous barrier to penetration. It is barrier to penetration from the surface is in the upper layers for water-soluble substances and the lower layers for lipid-soluble substances, and the barrier to the outward movement of water is in the lowest layer of the stratum corneum.

Membrane Potentials—Across the cell membrane there exists an electrical potential, always negative on the inside and positive on the outside. If a cell did not have special membrane electrolyte transport processes, its membrane potential would be mainly the result of the Donnan equilibrium (see Chapter 14) consequent to the semipermeability of the membrane. Such potentials generally lie between 2 and 5 mv.

A cell with a membrane across which diffusible electrolyte distribution is purely passive would be expected to have a high internal concentration of sodium, such as is true for the erythrocytes of some species. However, the interior of most cells is high in potassium and low in sodium, as depicted in Fig 37-8. This unequal distribution of cations attests to special electrolyte transport processes and to differential permeabilities of diffusible ions, so that the membrane potential is higher than that which would result from a purely passive Donnan distribution. In nerve and skeletal or cardiac muscle the membrane potential ranges upwards to about 90 mv. The electrical gradient is on the order of 50,000 v/cm, because of the extreme thinness of the membrane. Obviously, such an intense potential gradient will strongly influence the transmembrane passages of charged drug molecules.

Diffusion and Transport

Transport is the movement of a drug from one place to another within the body. The drug may diffuse freely in uncombined form with a kinetic energy appropriate to its thermal environment, or it may move in combination with extracellular or cellular constituents, sometimes in connection with energy-yielding processes that allow the molecule or complex to overcome barriers to simple diffusion.

Simple Nonionic Diffusion and Passive Transport—

TEVA EXHIBIT 1030

TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC




Fig 37-8. Simplified cross section of a cell membrane (components are not to scale). The lipid interior of the lamellar portion of the membrane consists of various phospholipids, fatty acids, cholesterol (c), and other steroids. Ions are indicated in order to illustrate differences in size relative to the channel. Pr: protein; Su: sugar.

Molecules in solution move in a purely random fashion, providing they are not charged and moving in an electrical gradient. Such random movement is called *diffusion*, and if the molecule is uncharged it is called *nonionic diffusion*.

In a population of drug molecules, the probability that during unit time any drug molecule will move across a boundary is directly proportional to the number of molecules adjoining that boundary and therefore to the drug concentration. Except at dilutions so extreme that only a few molecules are present, the actual rate of movement (molecules/unit time) is directly proportional to the probability and therefore to the concentration. Once molecules have passed through the boundary to the opposite side, their random motion may cause some to return and others to continue to move further away from the boundary. The rate of return is likewise proportional to the concentration on the opposite side of the boundary. It follows that, although molecules are moving in both directions, there will be a net movement from the region of higher to that of lower concentration and that the net transfer will be proportional to the concentration differential. If the boundary is a membrane, which has both substance and dimension, the rate of movement is also directly proportional to the permeability and inversely proportional to the thickness. These factors combine into Fick's Law of Diffusion,

$$\frac{dQ}{dt} = \frac{\bar{D}A(C_1 - C_2)}{x} \quad (5)$$

where Q is the net quantity of drug transferred across the membrane, t is time, C_1 is the concentration on one side and C_2 on the other, x is the thickness of the membrane, A is the area, and \bar{D} is the diffusion coefficient, related to permeability. The equation is more nearly correct if chemical activities are used instead of concentrations. Since a biological membrane is patchy, with pores of different sizes and probably with varying thickness and composition, both \bar{D} and x probably vary from spot to spot. Nevertheless, some mean values can be assumed.

It is customary to combine the membrane factors into a single constant, called a permeability constant or coefficient, P , so that $P = \bar{D}/x$, A in Eq 5 having unit value. The rate of net transport (diffusion) across the membrane then becomes

$$\frac{dQ}{dt} = P(C_1 - C_2) \quad (6)$$

As diffusion continues, C_1 approaches C_2 , and the net rate, dQ/dt , approaches zero in exponential fashion characteristic of a first-order process. Equilibrium is defined as that state in which $C_1 = C_2$. The equilibrium is, of course, dynamic, with equal numbers of molecules being transported in each direction during unit time. If water is also moving through the membrane, it may either facilitate the movement of drug or impede it, according to the relative directions of movement of water and drug; this effect of water movement is called *solvent drag*.

Ionic or Electrochemical Diffusion—If a drug is ionized, the transport properties are modified. The probability of penetrating the membrane is still a function of concentration, but it is also a function of the potential difference or electrical gradient across the membrane. A cationic drug molecule will be repelled from the positive charge on the outside of the membrane, and only those molecules with a high kinetic energy will pass through the ion barrier. If the cation is polyvalent, it may not penetrate at all.

Once inside the membrane, a cation will be simultaneously attracted to the negative charge on the intracellular surface of the membrane and repelled by the outer surface; it is said to be moving along the *electrical gradient*. If it is also moving from a higher towards a lower concentration, it is said to be moving along its *electrochemical gradient*, the electrochemical gradient being the sum of the influences of the electrical field and the concentration differential across the membrane.

Once inside the cell, cations will tend to be kept inside by the attractive negative charge on the interior of the cell, and the intracellular concentration of drug will increase until, by sheer numbers of accumulated drug particles, the outward diffusion or mass escape rate equals the inward transport rate, and electrochemical equilibrium is said to have occurred. At electrochemical equilibrium at body temperature (37°C), ionized drug molecules will be distributed according to the Nernst equation,

$$\pm \log \frac{C_o}{C_i} = \frac{ZE}{61} \quad (7)$$

where C_o is the molar extracellular and C_i the intracellular concentration, Z is the number of charges per molecule, and E is the membrane potential in millivolts. $\log C_o/C_i$ is positive when the molecule is negatively charged and negative when the molecule is positively charged.

Facilitated Diffusion—Sometimes a substance moves more rapidly through a biological membrane than can be accounted for by the process of simple diffusion. This accelerated movement is termed *facilitated diffusion*. It is thought to be due to the presence of a special molecule, called a *carrier*, within the membrane, with which carrier the transported substance combines. There is considered to be a greater permeability to the carrier-drug complex than to the drug alone, so that the transport rate is enhanced. After the complex traverses the membrane it dissociates. The carrier must either return to the original side of the membrane to be reused or be constantly produced on one side and eliminated on the other in order for the carrier process to be continuous. Many characteristics of facilitated diffusion formerly attributed to ion carriers can be explained by ion exchange. Although facilitated diffusion resembles active transport, below, in its dependence upon a continuous source of energy, it differs in that facilitated diffusion will only transport a molecule along its electrochemical gradient.

Active Transport—Active transport may be defined as energy-dependent movement of a substance through a biological membrane against an electrochemical gradient. It is characterized by the following:

1. The substance is transported from a region of lower to one of higher electrochemical activity.

2. Metabolic poisons interfere with transport.
3. The transport rate approaches an asymptote (ie, saturates) as concentration increases.
4. The transport system usually shows a requirement for specific chemical structures.
5. Closely related chemicals are competitive for the transport system.

Many drugs are secreted from the renal tubules into urine, from liver cells into bile or from the cerebrospinal fluid into blood by active transport, but the role of active transport of drugs in the distribution into most body compartments and tissues is less well known. Active transport is required for the penetration of a number of sympathomimetics into neural tissue.

Pinocytosis and Exocytosis—Many, perhaps all, cells are capable of a type of phagocytosis called *pinocytosis*. The cell membrane has been observed to invaginate into a saccular structure containing extracellular materials and then pinch off the saccule at the membrane, so that the saccule remains as a vesicle or vacuole within the interior of the cell. Since metabolic activity is required and since an extracellular substance may be transported against an electrochemical gradient, pinocytosis shows some of the same characteristics as active transport. However, pinocytosis is relatively slow and inefficient compared to most active transport, except in gastrointestinal absorption, in which pinocytosis is of considerable importance.

It is not known to what extent pinocytosis contributes to the transport of most drugs, but many macromolecules and even larger particles can be absorbed by the gut. Pinocytosis probably explains the oral efficacy of the Sabin polio vaccine. Some drugs themselves affect pinocytosis; for example, adrenal glucocorticoids markedly inhibit the process in macrophages and other cells involved in inflammation.

Exocytosis is more or less the reverse of pinocytosis. Granules, vacuoles or other organelles within the cell move to the cell membrane, fuse with it, and extrude their contents into the interstitial space.

Physicochemical Factors in Penetrance

Drugs and other substances may traverse the membrane primarily either through the pores or by dissociation into the membrane lipids and subsequent diffusion from the membrane into the cytosol or other fluid on the far side of the membrane. The physicochemical prerequisites are different according to which route is taken. To pass through the pores the "diameter" of the molecule must be smaller than the pore, but the molecule can be longer than the pore diameter. The probability that a long, thin molecule will be oriented properly is low, unless there is also bulk flow, and the transmembrane passage of large molecules is slow.

Water-soluble molecules with low lipid solubility are usually thought to pass through the membrane mainly via the pores and to a small extent by pinocytosis, but recent work with lipid monolayers suggests that small water-soluble molecules may also be able to pass readily through the lipid, and the necessity of postulating the existence of pores has been questioned. Nevertheless, experimental data on penetrance overwhelmingly favor the concept of passage of water-soluble lipid-insoluble substances through pores. If there is a membrane carrier or active transport system, a low solubility of the drug in membrane lipids is no impediment to penetration, since the drug-carrier complex is assumed to have an appropriate solubility, and energy from an active transport system enables the drug to penetrate the energy barrier "imposed by the lipids." Actually, the lipids are not an important energy barrier; rather the barrier is the force of attraction of the solvent water for its dipolar to polar solute, so that it is difficult for the solute to leave the water and enter the lipid.




Fig 37-9. The relationship of absorption of the unionized forms of drugs from the colon of the rat to the chloroform:water partition coefficient (courtesy, Schanker¹⁸).

Drugs with a high solubility in the membrane lipids, of course, pass easily through the membrane. Even when their dimensions are small enough to permit passage through pores, lipid-soluble drugs primarily pass through the membrane lipids, not only because chemical partition favors the lipid phase but because the surface area occupied by pores is only a small fraction of the total membrane area.

Lipid Solubility and Partition Coefficients—As early as 1902 Overton investigated the importance of lipid solubility to the penetrance and absorption of drugs. Eventually it was recognized that more important than lipid solubility was the lipid-water distribution coefficient; that is to say, a high lipid solubility does not favor penetrance unless the water solubility is low enough that the drug is not entrained in the aqueous phase.

In Fig 37-9 is illustrated the relationship between the chloroform-water partition coefficient and the colonic absorption of barbiturates. Chloroform is probably not the optimal lipid solvent for such a study, and natural lipids from nerve or other tissues have been shown to be superior in the few instances in which they have been employed. Nevertheless, the correlation shown in the figure is a convincing one.

When the water solubility of a substance is so low that a significant concentration in water or extracellular fluid cannot be achieved, absorption may be negligible in spite of a favorable partition coefficient. Hence mineral oil, petrolatum, etc. are virtually unabsorbed. The optimal partition coefficient for permeation of the skin appears to be lower than that for the permeation of the cell membrane, being perhaps as low as one.

Dipolarity, Polarity, and Nonionic Diffusion—The partition coefficient of a drug depends upon the polarity and the size of the molecule. Drugs with a high dipole moment, even though un-ionized, have a low lipid solubility and hence

Table I—Rates of Entry of Drugs in CSF and the Degrees of Ionization of Drugs at pH 7.4¹⁹

Drug	% binding to plasma protein	pK _a ^a	% unionized at pH 7.4	Permeability constant (P min ⁻¹) ± S.E.
<i>Drugs mainly ionized at pH 7.4</i>				
5-Sulfosalicylic acid	22	(strong)	0	<0.0001
N'-Methylnicotinamide	<10	(strong)	0	0.0005 ± 0.00006
5-Nitrosalicylic acid	42	2.3	0.001	0.001 ± 0.0001
Salicylic acid	40	3.0	0.004	0.006 ± 0.0004
Mecamylamine	20	11.2	0.016	0.021 ± 0.0016
Quinine	76	8.4	9.09	0.078 ± 0.0061
<i>Drugs mainly unionized at pH 7.4</i>				
Barbital	<2	7.5	55.7	0.026 ± 0.0022
Thiopental	75	7.6	61.3	0.50 ± 0.051
Pentobarbital	40	8.1	83.4	0.17 ± 0.014
Aminopyrine	20	5.0	99.6	0.25 ± 0.020
Aniline	15	4.6	99.8	0.40 ± 0.042
Sulfaguanidine	6	>10.0 ^b	>99.8	0.003 ± 0.0002
Antipyrine	8	1.4	>99.9	0.12 ± 0.013
N-Acetyl-4-aminoantipyrine	<3	0.5	>99.9	0.012 ± 0.0010

^a The dissociation constant of both acids and bases is expressed as a pK_a—a negative logarithm of the acidic dissociation constant.

^b Sulfaguanidine has a very weakly acidic group (pK_a > 10) and two very weakly basic groups (pK_a 2.75 and 0.5). Consequently, the compound is almost completely undissociated at pH 7.4.

poor penetrance. An example of a highly dipolar substance with a low partition coefficient and which does not penetrate into cells is sulfisoxazole. Sulfadiazine is somewhat less dipolar, has a chloroform-water partition coefficient ten times that of sulfisoxazole, and readily penetrates cells. Ionization not only greatly diminishes lipid solubility but may also impede passage through charged membranes (see *Ionic Diffusion*, page 724).

It is often stated that ionized molecules do not penetrate membranes, except for ions of small diameter. This is not necessarily true, because of the presence of membrane carriers for some ions, which carriers may effectively shield or neutralize the charge (ion-pair formation). The renal tubular transport systems, which transport such obligate ions as tetraethylammonium, probably form ion-pairs. Furthermore, if an ionized molecule has a large nonpolar moiety such that an appreciable lipid solubility is imparted to the molecule in spite of the charge, the drug may penetrate, although usually at a slow rate. For example, various morphinan derivatives are passively absorbed from the stomach even though they are completely ionized at the pH of gastric fluid. Nevertheless, when a drug is a weak acid or base, the unionized form with a favorable partition coefficient passes through a biological

membrane so much more readily than the ionized form that, for all practical purposes, only the unionized form is said to pass through the membrane. This has become known as the *principle of nonionic diffusion*.

This principle is the reason that only the concentrations of the unionized form of the barbiturates are plotted in Fig. 37-9.

For the purpose of further illustrating the principle, Table I is provided. In the table the permeability constants for penetrance into the cerebral spinal fluid of rats are higher for unionized drugs than for ionized ones. The apparent exceptions—barbital, sulfaguanidine, and acetylaminoantipyrine—may be explained by the dipolarity of the unionized molecules. With barbital, the two lipophilic ethyl groups are too small to compensate for the considerable dipolarity of the unionized barbituric acid ring; it may be also seen that barbital is appreciably ionized, which contributes to the relatively small permeability constant. Sulfaguanidine and acetylaminoantipyrine are both very polar molecules. Mecamylamine might also be considered an exception, since it shows a modest permeability even though strongly ionized; there is no dipolarity in mecamylamine elsewhere than the amino group.

Absorption of Drugs

Absorption is the process of movement of a drug from the site of application into the extracellular compartment of the body. Inasmuch as there is a great similarity among the various membranes that a drug may pass through in order to gain access to the extracellular fluid, it might be expected that the particular site of application (or *route*) would make little difference to the successful absorption of the drug. In actual fact, it makes a great deal of difference; many factors other than the structure and composition of the membrane determine the ease with which a drug is absorbed. These factors are discussed in the following sections, along with an account of the ways that drug formulations may be manipulated to alter the ability of a drug to be readily absorbed.

Routes of Administration

Drugs may be administered by many different routes. The various routes include oral, rectal, sublingual or buccal, par-

enteral, inhalation, topical, etc. The choice of a route depends upon both convenience and necessity.

Oral Route—This is obviously the most convenient route for access to the systemic circulation, providing that various factors do not militate against this route. Oral administration does not always give rise to sufficiently high plasma concentrations to be effective; some drugs are absorbed unpredictably or erratically; patients occasionally have an absorption malfunction. Drugs may not be given by mouth to patients with gastrointestinal intolerance, or who are in preparation for anesthesia, or who have had gastrointestinal surgery. Oral administration is also precluded in coma.

Rectal Route—Drugs that are ordinarily administered by the oral route usually can be administered by injection or by the alternative *lower enteral* route, through the anal portal into the rectum or lower intestine. With regard to the latter, *rectal suppositories* or *retention enemas* were formerly used quite frequently, but their popularity has abated somewhat




Fig 37-10. Blood concentration in mg/100 ml of theophylline (ordinates) following administration to humans of aminophylline in the amounts and by the routes indicated. Doses: per 70 kg. Theophylline-ethylenediamine by various routes: — intravenous, 0.5 g; - - - retention enema, 0.5 g; - · - · - oral tablets-Pl., 0.5 g; - - - oral tablets-Pl., 0.3 g; ···· rectal suppository, 0.5 g (courtesy, Trullitt, et al²⁰ adapted).

owing to improvements in parenteral preparations. Nevertheless, they continue to be valid and sometimes very important ways of administering a drug, especially in pediatrics and geriatrics. In Fig 37-10 the availability of a drug by retention enema may be compared with that by the intravenous route and by oral and rectal suppository administration. It is apparent that the retention enema may be a very satisfactory means of administration but that rectal suppositories may be inadequate where rapid absorption and high plasma levels are required. The illustration is not intended to lead the reader to the conclusion that a retention enema will always give more prompt and higher blood levels than the oral route, for converse findings for the same drug have been reported,²¹ but rather to show that the retention enema may offer a useful substitute for the oral route.

Sublingual or Buccal Route—Even though an adequate plasma concentration eventually may be achievable by the oral route, it may rise much too slowly for use in some situations where a rapid response is desired. In such situations parenteral therapy is usually indicated. However, the patients with angina pectoris may get quite prompt relief from an acute attack by the *sublingual* or *buccal* administration of nitroglycerin, so that parenteral administration may be avoided. When only small amounts of drugs are required to gain access to the blood, the buccal route may be very satisfactory, providing the physicochemical prerequisites for absorption by this route are present in the drug and dosage form. Only a few drugs may be given successfully by this route.

Parenteral Routes—These routes by definition include any route other than the oral-gastrointestinal (enteral) tract, but in common medical usage the term excludes topical administration and includes only various hypodermic routes. Parenteral administration includes the intravenous, intramuscular, and subcutaneous routes. Parenteral routes may be employed whenever enteral routes are contraindicated (see above) or inadequate.

The *intravenous* route may be preferred on occasion, even when a drug may be well absorbed by the oral route. There is no delay imposed by absorption before the administered drug reaches the circulation, and blood levels rise virtually as rapidly as the time necessary to empty the syringe or infusion bottle. Consequently, the intravenous route is the preferred route when an emergency calls for an immediate response.

In addition to the rapid rise in plasma concentration of drug, another advantage of intravenous administration is the greater predictability of the peak plasma concentration, which with some drugs can be calculated with a fair degree of precision. Smaller doses are generally required by the intravenous than by other routes, but this usually affords no advantage, inasmuch as the sterile injectable dose form costs more than enteric preparations, and the requirements for medical or paramedical supervision of administration may also add to the cost and inconvenience.

Because of the rapidity with which drug enters the circulation, dangerous side effects to the drug may occur which are often not extant by other routes. The principal untoward effect is a depression of cardiovascular function, which is often called *drug shock*. Consequently, some drugs must be given quite slowly to avoid vasculotoxic concentrations of drug in the plasma. Acute serious allergic responses are also more likely to occur by the intravenous route than by other routes.

Many drugs are too irritant to be given by the oral, intramuscular, or subcutaneous route, and must of necessity be given intravenously. However, such drugs may also cause damage to the veins (phlebitis) or, if extravasated, cause necrosis (slough) around the injection site. Consequently, such irritant drugs may be greatly diluted in isotonic solutions of saline, dextrose, or other media and given by slow infusion, providing that the slower rate of delivery does not negate the purpose of the administration in emergency situations.

Absorption by the *intramuscular* route is relatively fast, and this parenteral route may be used where an immediate effect is not required but a prompt effect is desirable. Intramuscular deposition may also be made of certain repository preparations, rapid absorption not being desired. Absorption from an intramuscular depot is more predictable and uniform than from a subcutaneous site.

Irritation around the injection site is a frequent accompaniment of intramuscular injection, depending upon the drug and other ingredients. Because of the dangers of accidental intravenous injection, medical supervision is generally required. Sterilization is necessary.

In *subcutaneous* administration the drug is injected into the alveolar connective tissue just below the skin. Absorption is slower than by the intramuscular route but nevertheless may be prompt with many drugs. Oftentimes, however, absorption by this route may be no faster than by the oral route. Therefore, when a fairly prompt response is desired, with some drugs the subcutaneous route may not offer much advantage over the oral route, unless for some reason the drug cannot be given orally.

The slower rate of absorption by the subcutaneous route is usually the reason why the route is chosen, and the drugs given by this route are usually those in which it is desired to spread the action out over a number of hours, in order to avoid either too intense a response, too short a response, or frequent injections. Examples of drugs given by this route are insulin and sodium heparin, neither of which is absorbed orally and both of which should be absorbed slowly over many hours. In the treatment of asthma, epinephrine is usually given subcutaneously to avoid the dangers of rapid absorption and consequent dangerous cardiovascular effects. Many repository preparations, including tablets or pellets, are given subcutaneously. As with other parenteral routes, irritation may occur. Sterile preparations are also required. However, medical supervision is not always required, and self-administration by this route is customary with certain drugs, such as insulin.

Intradermal injections, in which the drug is injected into rather than below the dermis is rarely employed, except in certain diagnostic and test procedures, such as screening for allergic or local irritant responses.

Occasionally, even by the intravenous route it is not possible, practical, or safe to achieve plasma concentrations high enough so that an adequate amount of drug penetrates into special compartments, such as the cerebrospinal fluid, or various cavities, such as the pleural cavity. The brain is especially difficult to penetrate with water-soluble drugs. The name *blood-brain barrier* is applied to the impediment to penetration. When drugs do penetrate, they are often secreted back into the blood very rapidly, so that adequate levels of drugs in the cerebrospinal fluid may be difficult to achieve. Consequently *intrathecal** or *intraventricular* administration may be indicated.

Body cavities such as the pleural cavity are normally wetted by a small amount of effusate which is in diffusion equilibrium with the blood and hence is accessible to drugs. However, infections and inflammations may cause the cavity to fill with serofibrinous exudate which is too large to be in rapid diffusion equilibrium with the blood. *Intracavitary* administration may thus be required. It is extremely important that sterile and nonirritating preparations be used for intrathecal or intracavitary administration.

Inhalation Route—Inhalation may be employed for delivering gaseous or volatile substances into the systemic circulation, as with most general anesthetics. Absorption is virtually as rapid as the drug can be delivered into the alveoli of the lungs, since the alveolar and vascular epithelial membranes are quite permeable, blood flow is abundant, and there is a very large surface for absorption.

Aerosols of nonvolatile substances may also be administered by inhalation, but the route is infrequently used for delivery into the systemic circulation, because of various factors that contribute to erratic or difficult-to-achieve blood levels. Whether or not an aerosol reaches and is retained in pulmonary alveoli depends critically upon particle size: particles greater than 1 μm in diameter tend to settle in the bronchioles and bronchi, whereas particles less than 0.5 μm fail to settle and are mainly exhaled. Aerosols are mostly employed when the purpose of administration is an action of the drug upon the respiratory tract itself. An example of a drug commonly given as an aerosol is isoproterenol, which is employed to relax the bronchioles in asthma.

Topical Route—Topical administration is employed to deliver a drug at or immediately beneath the point of application. Although occasionally enough drug is absorbed into the systemic circulation to cause systemic effects, absorption is too erratic for the topical route to be used for systemic therapy. Recent work with aprotic solvent vehicles such as dimethyl sulfoxide (DMSO) has, however, renewed interest in topical administration for systemic effects. A large number of topical medicaments are applied to the skin, although topical drugs are also applied to the eye, nose and throat, ear, vagina, etc.

In man, percutaneous absorption probably occurs mainly from the surface. Absorption through the hair follicles occurs, but the follicles in man occupy too small a portion of the total integument to be of primary importance. Absorption through sweat and sebaceous glands generally appears to be minor. When the medicament is rubbed on vigorously, the amount of the preparation that is forced into the hair follicles and glands is increased. Rubbing also forces some material through the stratum corneum without molecular dispersion and diffusion through the barrier. Rather large particles of substances such as sulfur have been demonstrated to pass intact through the stratum corneum. When the skin is diseased or abraded, the cutaneous barrier may be disrupted or

defective, so that percutaneous absorption may be increased. Since much of a drug that is absorbed through the epidermis diffuses into the circulation without reaching a high concentration in some portions of the dermis, systemic administration may be preferred in lieu of or in addition to topical administration.

Factors That Affect Absorption

In addition to the physicochemical properties of drug molecules and biological membranes, various factors affect the rate of absorption and determine, in part, the choice of route of administration.

Concentration—It is self-evident that the concentration, or, more exactly, the thermodynamic activity, of a drug in a drug preparation will have an important bearing upon the rate of absorption, since the rate of diffusion of a drug away from the site of administration is directly proportional to the concentration. Thus a 2% solution of lidocaine will induce local anesthesia more rapidly than a 0.2% solution. However, drugs administered in solid form are not necessarily absorbed at the maximal rate (see *Physical State of Formulation and Dissolution Rate* below).

After oral administration the concentration of drugs in the gut is a function of the dose, but the relationship is not necessarily linear. Drugs with a low aqueous solubility (eg, digitoxin) quickly saturate the gastrointestinal fluids, so that the rate of absorption tends to reach a limit as the dose is increased. The peptizing and solubilizing effects of bile and other constituents of the gastrointestinal contents assist in increasing the rate of absorption but are in themselves somewhat erratic. Furthermore, many drugs affect the rates of gastric, biliary, and small intestinal secretion, which causes further deviations from a linear relationship between concentration and dose.

Drugs that are administered subcutaneously or intramuscularly also may not always show a direct linear relationship between the rate of absorption and the concentration of drug in the applied solution, because osmotic effects may cause dilution or concentration of the drug, if the movement of water or electrolytes is different from that of the drug. Whenever possible, drugs for hypodermic injection are prepared as isotonic solutions. Some drugs affect the local blood flow and capillary permeability, so that at the site of injection there may be a complex relationship of concentration achieved to the concentration administered.

Physical State of Formulation and Dissolution Rate—The rate of absorption of a drug may be greatly affected by the rate at which the drug is made available to the biological fluid at the site of administration. The intrinsic physicochemical properties, such as solubility and the thermodynamics of dissolution, are only part of the factors which affect the rate of dissolution of a drug from a solid form. Other factors include not only the unavoidable interactions among the various ingredients in a given formulation but also deliberate interventions to facilitate dispersion (eg, comminution, Chapter 76, and dissolution, Chapter 35) or retard it (eg, coatings, Chapter 91, and slow-release formulations, Chapter 92). There are also factors that affect the rate of delivery from liquid forms. For example, a drug in a highly viscous vehicle is more slowly absorbed from the vehicle than a drug in a vehicle of low viscosity; in oil-in-water emulsions, the rate depends upon the partition coefficient. These manipulations are the subject of biopharmaceutics (see Chapter 92).

Area of Absorbing Surface—The area of absorbing surface is an important determinant of the rate of absorption. To the extent that the therapist must work with the absorbing surfaces available in the body, the absorbing surface is not

* Intrathecal administration denotes administration into the cerebrospinal fluid at any level of the cerebrospinal axis, including injection into the cerebral ventricles, which is the most common mode of intrathecal administration.

subject to manipulation. However, the extent to which the existing surfaces may be utilized is subject to variation. In those rare instances in which percutaneous absorption is intended for systemic administration, the entire skin is available.

Subsequent to subcutaneous or intramuscular injections, the site of application may be massaged in order to spread the injected fluid from a compact mass to a well-dispersed deposit. Alternatively, the dose may be divided into multiple small injections, although this recourse is generally undesirable.

The different areas for absorption afforded by the various routes account, in part, for differences in the rates of absorption by those routes. The large alveolar surface of the lungs allows for extremely rapid absorption of gases, vapors, and properly aerosolized solutions; with some drugs the rate of absorption may be nearly as fast as intravenous injection. In the gut the small intestine is the site of the fastest, and hence most, absorption because of the small lumen and highly developed villi and microvilli; the stomach has a relatively small surface area, so that even most weak acids are predominately absorbed in the small intestine despite a pH partition factor that should favor absorption from the stomach (see *The pH Partition Principle*, page 731).

Vascularity and Blood Flow—Although the thermal velocity of a freely diffusible average drug molecule is on the order of meters per second, in solution the rate at which it will diffuse away from a reference point will be much slower; collisions with water and/or other molecules, which causes a random motion, and the forces of attraction between the drug and water or other molecules slow the net mean velocity.

The time taken to traverse a given distance is a function of the square of the distance; on the average it would take about $\frac{1}{100}$ sec for a net outward movement of $1 \mu\text{m}$, 1 sec for $10 \mu\text{m}$, 100 sec for $100 \mu\text{m}$, etc. In a highly vascular tissue, such as skeletal muscle, in which there may be more than 1000 capillaries/sq mm of cross section, a drug molecule would not have to travel more than a few microns, hence less than a second on the average, to reach a capillary from a point of injection.

Once the drug reaches the blood, diffusion is not important to transport, and the rate of blood flow determines the movement. The velocity of blood flow in a capillary is about 1 mm/sec, which is 100 times faster than the mean net velocity of drug molecules 1 mm away from their injection site. The velocity of blood flow is even faster in the larger vessels. Less than a minute is required to distribute drug molecules from the capillaries at the injection site to the rest of the body.

From the above discussion it follows that absorption is most rapid in the vascular tissues. Drugs are absorbed more rapidly from intramuscular sites than from less vascular subcutaneous sites, etc. Despite the small absorbing surface for buccal or sublingual absorption, the high vascularity of the buccal, gingival, and sublingual surfaces favors an unexpectedly high rate of absorption. Because of hyperemia, absorption will be faster from inflamed than from normal areas, unless the presence of edema lengthens the mean distance between capillaries and thus negates the effects of hyperemia on absorption.

Vasoconstriction may have a profound effect upon the rate of absorption. When a local effect of a drug is desired, as in local anesthesia, absorption away from the infiltrated site may be greatly impeded by vasoconstrictors included in the preparation. Unwanted vasoconstriction sometimes may cause serious problems. For example, in World War II many wounded soldiers were given subcutaneous morphine without evident effect. As a result, injections were sometimes repeated more than once. When the patient was removed to the field hospital, toxic effects would suddenly occur. The explanation is that cold-induced vasoconstriction occurred in the field; when the patient was warmed in the hospital,

vasodilation would result and the victim would be flooded with drug. Shock also contributes to the effect, since during shock the blood flow is diminished, and there may also be a superimposed vasoconstriction; repair of the shock condition then facilitates absorption.

Molecules too large to pass through the capillary endothelium will of necessity enter the systemic circulation through the lymph. Thus the lymph flow may be important to the absorption of a few drugs.

Movement—A number of factors combine so that movement at the site of injection increases the rate of absorption. In the intestine, segmental movements and peristalsis aid in dividing and dispersing the drug mass. The continual mixing of the chyme helps keep the concentration maximal at the mucosal surface. The pressures developed during segmentation and peristalsis may also favor a small amount of filtration. Movement at the site of hypodermic injection also favors absorption, since it tends to force the injected material through the tissue, increasing the surface area of drug mass and decreasing the mean distance to the capillaries. Movement also increases the flow of blood and lymph. The selection of a site for intramuscular injection may be determined by the amount of expected movement, according to whether the preparation is intended as a fast-acting or a repository preparation.

Gastric Motility and Emptying—The motility of the stomach is more important to the rate at which an orally administered drug is passed on to the small intestine than it is to the rate of absorption from the stomach itself, since for various reasons, noted above, absorption from the stomach is usually of minor importance.

The average emptying time of the unloaded stomach is about 40 min, and the half-time is around 10 min, though it varies according to its contents, reflex and psychological factors, the action of certain autonomic drugs, or disease. The effect of food to delay absorption is due in part to its action to prolong emptying time. The emptying time causes a delay in the absorption of drug, which may be unfavorable or favorable according to what is desired. In the case of therapy with antacids, gastric emptying is a nuisance, since it removes the antacid from the stomach where it is needed.

Solubility and Binding—The dissolution of drugs of low solubility is generally a slow process. Indeed, low solubility is the result of a low rate of departure of drug molecules from the undispersed phase. Furthermore, since the concentration around the drug mass is low, the concentration gradient from the site of deposition to the plasma is small, and the rate of diffusion is low, accordingly.

When it is desired that a drug have a prolonged action but not a high plasma concentration, a derivative of low solubility is often sought. The "insoluble" estolates and other esters of several steroids have durations of action of weeks because of the slow rates of absorption from the sites of injection. Insoluble salts or complexes of acidic or basic drugs are also employed as repository preparations; for example, the procaine salt of penicillin G has a low solubility and is used in a slow release form of the antibiotic.

The solubility of certain macromolecules is critically dependent on the ionization of substituent groups. When they are amphiprotic, they are least soluble at their isoelectric pH. Insulin is normally soluble at the pH of the extracellular fluid; but by combining insulin with the right proportion of a basic protein, such as protamine, the isoelectric pH can be made to be approximately 7.4, and the complex can be used as a low-solubility prolonged-action drug. For more details, see Chapter 92.

Some drugs may bind with natural substances at or near the site of application. The strongly ionized mucopolysaccharides in connective tissue, ground substance, and mucous secretions of the gut are retardants to the absorption of a number of

Handwritten note: }
NPH
15/6

drugs, especially large cationic or polycationic molecules. In the gut, the binding is the least at low pH, which should favor absorption of large cations from the stomach; however, absorption from the stomach is slow (see above), so that the absorption of large cations mainly occurs in the upper duodenum where the pH is still relatively low. Pharmacologically inactive quaternary ammonium compounds are sometimes included in an oral preparation of a quaternary ammonium drug for the purpose of saturating the binding sites of mucin and other mucopolysaccharides and thereby enhancing the absorption of drug.

In addition to mucopolysaccharides in mucous secretions, food in the gastrointestinal tract binds many drugs and slows absorption. Antacids, especially aluminum hydroxide plus other basic aluminum compounds and magnesium trisilicate, bind amine and ammonium drugs and interfere with absorption.

Donnan Effect—The presence of a charged macromolecule on one side of a semipermeable membrane (impermeable to the macromolecule) will alter the concentration of permeant ionized particles according to the Donnan equilibrium (page 732). Accordingly, drug molecules of the same charge as the macromolecule will be constrained to the opposite side of the membrane. The presence of appropriately charged macromolecules not only will influence the distribution of drug ions in accordance with the Donnan equation but will increase the rate of transfer of the drug across the membrane, because of mutual ionic repulsion. This effect is sometimes used to facilitate the absorption of ionizable drugs from the gastrointestinal tract. The Donnan effect also operates to retard the absorption of drug ions of opposite charge; however, the mutual electrostatic attraction of a macromolecule and drug ion generally results in actual binding, which is more important than the Donnan effect.

Vehicles and Absorption Adjuvants—Drugs that are to be applied topically to the skin and mucous membranes are often dissolved in vehicles that are thought to enhance the penetration. For a long time it was thought that oleaginous vehicles promoted the absorption of lipid-soluble drugs. However, the role and effect of the vehicle has proven to be quite complex. In the skin at least five factors are involved:

1. The effect of the vehicle to alter the hydration of the keratin in the barrier layer.
2. The effect of the vehicle to promote or prevent the collection of sweat at the surface of the skin.
3. The partition coefficient of the drug in a vehicle-water system.
4. The permeability of the skin to the undissolved drug.
5. The permeability of the skin to the vehicle.

The effect of the vehicle to aid in the access of the drug to the hair follicles and sebaceous glands may also be involved, although in man the follicles and glands are probably ordinarily of minor importance to absorption.

A layer of oleaginous material over the skin prevents the evaporation of water, so that the stratum corneum may become macerated and more permeable to drugs. In dermatology it is even sometimes the practice to wrap the site of application with Saran wrap or some other waterproof material for the purpose of increasing the maceration of the stratum corneum. However, the layer of perspiration that forms under an occlusive vehicle may itself become a barrier to the movement of lipid-soluble drugs from the vehicle to the skin, but it may facilitate the movement of water-soluble

drugs. Conversely, polyethylene glycol vehicles remove the perspiration and dehydrate the barrier, which decreases the permeability to drugs; such vehicles remove the aqueous medium through which water-soluble drugs may pass down into the stratum corneum but at the same time facilitate the transfer of lipid-soluble drugs from the vehicle to the skin.

Even in the absence of a vehicle it is not clear what physicochemical properties of a drug favor cutaneous penetration, high lipid-solubility being a prerequisite according to some authorities and an ether-water partition coefficient of approximately 1 according to others. Yet the penetrances of ethanol and dibromomethane are nearly equal, and other such enigmas exist. It is not surprising, then, that the effects of vehicles are not altogether predictable.

A general statement might be made that if a drug is quite soluble in a poorly absorbed vehicle, the vehicle will retard the movement of the drug into the skin. For example, salicylic acid is 100 times as permeant when absorbed from water than from polyethylene glycol, and pentanol is 5 times as permeant from water as from olive oil. Yet ethanol penetrates 5 times faster from olive oil than from either water or ethanol, all of which denies the trustworthiness of generalizations about vehicles.

In recent years there has been much interest in certain highly dielectric aprotic solvents, especially dimethyl sulfoxide (DMSO). Such substances generally prove to be excellent solvents for both water- and lipid-soluble compounds and for some compounds not soluble in either water or lipid solvents. The extraordinary solvent properties are probably due to a high polarizability and van der Waals bonding capacity, a high degree of polarization (dipole moment), and a lack of association through hydrogen bonding. As a vehicle, DMSO greatly facilitates the permeation of the skin and other biological membranes by numerous drugs, even including such large molecules as insulin. The mechanism is not understood. Such vehicles have a potential for many important uses, but they are at present only experimental, pending further investigations on toxicity.

From time to time a claim is made that a new ingredient of a tablet or elixir enhances the absorption of a drug, and a comparison of plasma levels of the old and new preparations seems to support the claim. Upon further investigation, however, it may be revealed that the new so-called absorption adjuvant is replacing an ingredient that previously bound the drug or delayed its absorption; thus the new "adjuvant" is not an adjuvant but rather it is only a nondeterrent.

Other Factors—A number of other less-well-defined factors affect the absorption of drugs, some of which may operate, in part, through factors already cited above. Disease or injury has a considerable effect upon absorption. For example, debridement of the stratum corneum increases the permeability to topical agents, meningitis increases the permeability of the blood-brain barrier, biliary insufficiency decreases the absorption of lipid-soluble substances from the intestine, acid-base disturbances can affect the absorption of weak acids or bases, etc. Certain drugs, such as ouabain, that affect active transport processes may interfere with the absorption of certain other drugs. The condition of the ground substance, or "intracellular cement" probably bears on the absorption of certain types of molecules. Hyaluronidase, which depolymerizes the mucopolysaccharide ground substance, can be demonstrated to facilitate the absorption of some, but not all, drugs from subcutaneous sites.

Drug Disposition

The term *drug disposition* is used here to include all processes which tend to lower the plasma concentration of drug,

as opposed to drug absorption, which elevates the plasma level. Consequently, the distribution of drugs to the various

tissues will be considered under Disposition. Some authors use the term disposition synonymously with elimination, that is, to include only those processes which decrease the amount of drug in the body. In the present context, disposition comprises three categories of processes: distribution, biotransformation, and excretion.

Distribution, Biotransformation, and Excretion

The term *distribution* is self-explanatory. It denotes the partitioning of a drug among the numerous locations where a drug may be contained within the body. *Biotransformations* are the alterations in the chemical structure of a drug that are imposed upon it by the life processes. *Excretion* is, in a sense, the converse of absorption, namely, the transportation of the drug or its products out of the body. The term applies whether or not special organs of excretion are involved.

Distribution

The body may be considered to comprise a number of compartments: enteric (gastrointestinal), plasma, interstitial, cerebrospinal fluid, bile, glandular secretions, urine, storage vesicles, cytoplasm or intracellular space, etc. Some of these "compartments," such as urine and secretions, are open-ended, but since their contents relate to those in the closed compartments, they must also be included.

At first thought it may seem that if a drug were passively distributed (ie, by simple diffusion) and the plasma concentration could be maintained at a steady level, the concentration of a drug in the water in all compartments ought to become equal. It is true that some substances, such as ethanol and antipyrine, are distributed nearly equally throughout the body water, but they are more the exception than the rule. Such substances are mainly small, uncharged, nondissociable, highly water-soluble molecules.

The condition of small size and high water solubility allows for passage through the pores without the necessity of carrier or active transport. Small size also places a limit on van der Waals binding energy and configurational complementarity, so that binding to proteins in plasma or cells is slight. The presence of a charge on a drug molecule makes for unequal distribution across charged membranes, in accordance with the Donnan distribution. Dissociability causes unequal distribution when there is a pH differential between compartment, as discussed under *The pH Partition Principle* (see below). Thus, even if a drug is distributed passively, its distribution may be uneven throughout the body. When active transport into or a rapid metabolic destruction occurs within some compartments, uneven distribution is also inevitable.

The pH Partition Principle—An important consequence of nonionic diffusion is that a difference in pH between two compartments will have an important influence upon the partitioning of a weakly acidic or basic drug between those compartments. The partition is such that the unionized form of the drug has the same concentration in both compartments, since it is the form that is freely diffusible; the ionized form in each compartment will have the concentration that is determined by the pH in that compartment, the pK, and the concentration of the unionized form. The governing effect of pH and pK on the partition is known as the *pH partition principle*.

To illustrate the principle, consider the partition of salicylic acid between the gastric juice and the interior of a gastric mucosal cell. Assume the pH of the gastric juice to be 1.0,




Fig 37-11. Hypothetical partition of salicylic acid between gastric juice and the cytoplasm of a gastric mucosal cell. It is assumed that the ionized form cannot pass through the cell membrane. The intragastric concentration of salicylic acid is arbitrarily arranged to provide unit concentration of the unionized form. Bracketed values: concentration; arrows: relative size depicts the direction in which dissociation-association is favored at equilibrium.

which it occasionally becomes. The pK_a of salicylic acid is 3.0 (Martin²² provides one source of pK values of drugs). With the Henderson-Hasselbalch equation (see page 244) it may be calculated that the drug is only 1% ionized at pH 1.0.* The intracellular pH of most cells is about 7.0. Assuming the pH of the mucosal cell to be the same, it may be calculated that salicylic acid will be 99.99% ionized within the cells. Since the concentration of the unionized form is theoretically the same in both gastric juice and mucosal cells, it follows that the total concentration of the drug (ionized + unionized) within the mucosal cell will be 10,000 times that in gastric juice. This is illustrated in Fig 37-11. Such a relatively high intracellular concentration can have important osmotic and toxicologic consequences.

Had the drug been a weak base instead of an acid, the high concentration would have been in the gastric juice. In the small intestine, where the pH may range from 7.5 to 8.1, the partition of a weak acid or base will be the reverse of that in the stomach, but the concentration differential will be less, because the pH differential from lumen to mucosal cells, etc., will be less. The reversal of partition as the drug moves from the stomach to the small intestine accounts for the phenomenon that some drugs may be absorbed from one gastrointestinal segment and returned to another. The weak base, atropine, is absorbed from the small intestine, but because of pH partition it is "secreted" into the gastric juice.

The pH partition of drugs has never been demonstrated to be as marked as that illustrated in Fig 37-11 and in the text. Not only do many drug ions probably pass through the pores of the membrane to a significant extent, but some may also pass through the lipid phase, as explained above for the morphinans and mecamylamine. Furthermore, ion-pair formation in carrier transport also bypasses nonionic diffusion. All processes that tend toward an equal distribution of drugs across membranes and among compartments will cause further deviations from theoretical predictions of pH partition.

* The relationship of ionization and partition to pH and pK has been formulated in several different ways, but the student may calculate the concentrations from simple mass law equations. More sophisticated calculations and reviews of this subject are available.^{18,23-28}

Electrochemical and Donnan Distribution—A drug ion may be passively distributed across a membrane in accordance with the membrane potential, the charge on the drug ion, and the Donnan effect. The relationship of the membrane potential to the passive distribution of ions is quantitatively expressed by the Nernst equation (Eq 7, page 724) and has already been discussed. Barring active transport, pH partition, and binding, the drug will be said to be distributed according to the electrical gradient or to its "equilibrium" potential. If the membrane potential is 90 mv, the concentration of a univalent cation will be 30 times as high within the cell as without; if the drug cation is divalent, the ratio will be 890. The distribution of anions would be just the reverse. If the membrane potential is but 9 mv, the ratio for a univalent cation will be only 1.4 and for a divalent cation only 2.0. It can thus be seen how important membrane potential may be to the distribution of ionized drugs.

It was pointed out under *Membrane Potentials*, page 723, that large potentials derive from active transport of ions but that small potentials may result from Donnan distribution. Donnan membrane theory is discussed in Chapter 14. According to the theory, the ratio of the intracellular/extracellular concentration of a permeant univalent anion is equal to the ratio of extracellular/intracellular concentration of a permeant univalent cation. A more general mathematical expression that includes ions of any valence is

$$\left(\frac{A_i}{A_e}\right)^{1/Z_a} = \left(\frac{C_e}{C_i}\right)^{1/Z_c} = r \quad (8)$$

where A_i is the intracellular and A_e the extracellular concentration of anion, Z_c is the valence of cation, Z_a is the valence of anion, C_i is the intracellular and C_e the extracellular concentration of cation, and r is the Donnan factor. The value of r depends upon the average molecular weight and valence of the macromolecules (mostly protein) within the cell, and the intracellular and extracellular volumes. Since the macromolecules within the cell are negatively charged, the cation concentration will be higher within the cell, that is, $C_i > C_e$. Since a Donnan distribution results in a membrane potential, the distribution of drug ion will also be in keeping with the membrane potential.

The Donnan distribution also applies to the distribution of a charged drug between the plasma and interstitial compartment, because of the presence of anionic proteins in the plasma. Eq 8 applies by changing the subscript i to p , for plasma, and e to i , for interstitial. The Donnan factor, r , for plasma-interstitial space partition is about 1.05:1.

Binding and Storage—Drugs are frequently bound to plasma proteins (especially albumin), interstitial substances, intracellular constituents, and bone and cartilage. If binding is extensive and firm, it will have a considerable impact upon the distribution, excretion, and sojourn of the drug in the body. Obviously, a drug that is bound to a protein or any other macromolecule will not pass through the membrane in the bound form; only the unbound form can negotiate among the various compartments.

The partition among compartments is determined by the binding capacity and binding constant in each compartment. As long as the binding capacity exceeds the quantity of drug in the compartment, the following equation generally applies:

$$\log D_b = \log K + a \log D_f \quad (9)$$

where D_b is the concentration of bound drug, D_f is the concentration of free drug, and a and K are constants characteristic of the drug and binding macromolecule. The equation is that of a Freundlich isotherm. As the binding capacity is approached, the relationship no longer holds. For a nondissociable drug at equilibrium, D_f will be the same in all com-




Fig 37-12. Distribution of a drug between two compartments between which the degrees of binding to protein differ. The percent of binding is indicated. Only the unbound drug can pass through the membrane. Bracketed values: concentration (courtesy, Schanker²⁴).

municating compartments, so that it would be possible to calculate the partition if K and a are known for each compartment. Except for plasma, the values of a and K are generally unknown, but the percent bound is often known. From the percent bound the partition can also be calculated, as in Fig 37-12. However, the logarithmic relationships shown in Eq 9 serve as a reminder that the percent bound changes with the concentration, so that the partition will vary with the dose. If the drug is a weak acid or base, the unionized free form negotiates among the compartments, but the ionized form is often the more firmly bound, and calculations must take into account the dissociation constant and the different a 's and K 's of the ionized and unionized forms.

It is commonly misbelieved that binding in the plasma interferes with the activity of a drug and the intracellular binding in a responsive cell increases activity or toxicity. Both binding in plasma and in the tissues decreases the concentration of free drug; but this is easily remedied by adjusting the dose to give a sufficient concentration for pharmacological activity. The distribution and activity of the free form is not affected by binding. The principal effect of binding is to increase the initial dose requirement for drug and to create a reservoir of drug from which the drug may be withdrawn as the free form is excreted or metabolized. However, if the binding is extremely firm and release is slow, the rate of release may not be enough to sustain the free form at a sufficient level for pharmacological activity; in such instances the bound drug cannot be considered a reserve.

The effect of binding upon the sojourn of a drug may be considerable. For example, quinacrine, which may be concentrated in the liver to as much as several thousand times the concentration in plasma, may remain in the body for months. Some iodine-containing radiopaque diagnostic agents are strongly bound to plasma protein and may remain in the plasma for as long as 2 years. In pathological conditions, such as nephrosis, diabetes, and cirrhosis, in which plasma protein levels may be decreased, the plasma protein binding, loading dose, and duration of action may all be decreased.

If a drug is bound to a functional macromolecule, binding may relate to pharmacological activity and toxicity, provided that the binding is at a critical center of the macromolecule. The binding by nucleic acids of certain antimalarials, such as quinacrine, undoubtedly contributes to the parasitocidal actions as well as to toxicity.

Most drugs are bound to proteins by relatively weak forces, such as van der Waals (London, Keesom, or Debye) forces, or hydrogen or ionic bonds. Consequently, binding constants are generally small and binding is usually readily reversible. The larger the molecule, the greater the van der Waals bonding, so that large drug molecules are more likely to be strongly bound than are small ones.

Just as shape and the nature of functional groups is important to drug-receptor combination, so they also are to




Fig 37-13. Predisposition of thiopental for fat. 25 mg/kg was given to a dog. After a brief sojourn of thiopental in the more vascular tissues, it gradually transfers to fat, where the lipid-soluble drug dissolves in fat droplets (courtesy, Brodie and Hogben²⁵).

binding. Drugs of similar shape and/or chemical affinities may bind at the same sites on a binding protein and hence compete with one another. For example, phenylbutazone displaces warfarin from human plasma albumin, which may cause an increase in the anticoagulant effect of warfarin. Some drugs may also displace protein-bound endogenous constituents. For example, sulfisoxazole displaces bilirubin from plasma proteins; in infants with kernicterus the freed bilirubin floods the central nervous system and causes sometimes fatal toxicity.

According to the lipid-water coefficient, a drug may be taken up into fat. The ratio of concentration in fat to that in plasma will not be the same as the partition coefficient because of the content of water and of non-lipids in adipose tissue and because electrolytes and other solutes alter the dielectric constant and hence solubilities from those of pure water. Lipoproteins and even nonpolar substituents on plasma proteins also take up lipid-soluble molecules, so that solubility in plasma can be considerably higher than that in water. The relatively high solubility of ether in plasma makes plasma a pool for ether, the filling of which delays the onset of anesthesia. However, ether and other volatile anesthetics are gradually taken up into the adipose tissue, which acts as a store of the anesthetic. The longer the anesthetic is administered, the greater the store and the longer it takes for anesthesia to terminate when inhalation has been discontinued.

Another notable substance that it readily taken up into fat is thiopental. Even though there is a high solubility of this barbiturate in fat, the low rate of blood flow in fat limits the rate of uptake. Because the blood flow in the brain is very high, thiopental rapidly enters brain tissue. However, it soon equilibrates with the other tissues, and the brain concentration falls as that in the other tissues (eg, muscle, liver) increases. Gradually, however, the fat accumulates the drug at the expense of other compartments. The gradual entry of thiopental into fat at the expense of plasma, muscle, or liver is illustrated in Fig 37-13.

Nonequilibrium and Redistribution—Thus far the distribution of drugs has been mainly discussed as though equilibrium or steady state conditions exist after a drug is absorbed and distributed. However, since most drugs are administered at intervals and the body content of drug rises and falls with absorption and destruction-excretion, neither a true equilibrium among the body compartments nor a steady state exists.

The term equilibrium is misleadingly used to describe the conditions that exist when the plasma concentration and the concentration in a tissue are equal, as exemplified at the point of intersection of the curves for plasma and muscle or plasma and fat in Fig 37-13. But such "equilibrium" with fat occurs much later than "equilibrium" with muscle, so that no true equilibrium really exists among all the compartments. Fur-

thermore, the cross-over point for plasma and any one tissue is not necessarily an equilibrium point, because the rates of ingress and egress from the tissue are not necessarily equal when the internal and external concentrations are equal, since there are numerous factors that make for unequal distribution (pH partition, Donnan effect, electrochemical distribution, active transport, binding, etc).

A study of Fig 37-13 shows that the distribution of thiopental continually changed during the 3½ hr of observation. At the end of the period, the content in fat was still increasing while that in each of the other compartments was decreasing. This time-dependent shift in partition is called *redistribution*. Eventually, the content in fat would have reached a peak, which peak would represent as nearly a true equilibrium point as could be achieved in the dynamic situation where metabolic destruction and a slight amount of excretion of the drug was taking place. Once the concentration in the fat had reached its peak, its content would have declined in parallel with that in the other tissues, and the partition among the compartments would have remained essentially constant. Redistribution, then, takes place only until the concentration in the slowest filling compartment reaches its peak, so long as the kinetics of elimination are constant.

An index of distribution known as the *volume of distribution* (amount of drug in the body divided by plasma concentration) is of considerable usefulness in pharmacokinetics but is of limited value in defining the way in which a drug is partitioned in the body. Volume of distribution is discussed on page 756.

The word *space* is often used synonymously with volume of distribution. It is especially employed when the distributed substance has a volume of distribution that is essentially identical to a physical real space or body compartment. *N*-Acetyl-4-aminoantipyrine is distributed evenly throughout the total body water and is not bound to proteins or other tissue constituents. Thus the acetylaminopyrine space or volume of distribution coincides with that of total body water. Inulin, sucrose, sulfate, and a number of other substances are essentially confined to extracellular water, so that an inulin space, for example, measures the extracellular fluid volume. Evans blue is confined to the plasma, so that the Evans blue space is the plasma volume. Such space measurements with standard space indicators are a necessary part of studies on the distribution of drugs, since it is desirable to compare the volume of distribution to a drug to the standard spaces.

Biotransformations

Most drugs are acted upon by enzymes in the body and converted to metabolic derivatives called metabolites. The process of conversion is called biotransformation. Metabolites are usually more polar and less lipid-soluble than the parent drug because of the introduction of oxygen into the molecule, hydrolysis to yield more highly polar groups, or conjugation with a highly polar substance. As a consequence, metabolites often show less penetrance into tissues and less renal tubular resorption than the parent drug, in accordance with the principle of the low penetrance of polar and high penetrance of lipid-soluble substances. For similar reasons, metabolites are usually less active than the parent drug, often inactive; even if they are appreciably active, they are generally more rapidly excreted. Therefore, the usual net effect of biotransformation may be said to be one of *inactivation* or *detoxication*.

There are, however, numerous examples in which biotransformation does not result in inactivation. Table III (page 758) lists a number of drugs that generate active metabolites; in a few instances activity derives entirely from the metabolite.

There are also examples in which the parent drug has no activity of its own but is converted to an active metabolite. Parathion, malathion, and certain other anticholinesterases require metabolic activation, inactive chloroguanide is converted to an active triazine derivative, phenylbutazone is hydroxylated to the antirheumatic hydroxyphenylbutazone, inactive pentavalent arsenicals are reduced to their active trivalent metabolites, and there are other examples of an activating biotransformation.

When a delayed or prolonged response to a drug is desired or an unpleasant taste or local reaction is to be avoided, it is a common pharmaceutical practice to prepare an inactive or nonoffending precursor, such that the active form may be generated in the body. This practice has been termed *drug latention*. Chloramphenicol palmitate, dichloralphenazone, and the estolates of various steroid hormones are examples of deliberately latentiated drugs. Because inactive metabolites do not always result from biotransformation, the term detoxication should not be used as a synonym for biotransformation.

Biotransformations take place principally in the liver, although the kidney, skeletal muscle, intestine, or even plasma may be important sites of the enzymatic attack of some drugs. Since plasma lacks the enzymes and structures required for electron transport, biotransformations in plasma are mostly hydrolytic.

Endoplasmic Reticulum and Microsomal System—Biotransformations in the liver mainly occur in *smooth endoplasmic reticulum*. The endoplasmic reticulum is a tubular system which courses through the interior of the cell but also appears to communicate with the interstitial space, and its membrane is continuous with the cell membrane. Some of the reticulum is lined with ribonucleoprotein particles, called ribosomes, which are engaged in protein synthesis; this is the *rough* endoplasmic reticulum. Although the smooth endoplasmic reticulum lacks such a granular appearance, it is heavily invested with numerous enzymes which biotransform many drugs and some endogenous substances.

When a broken cell homogenate of the liver is prepared, the reticulum becomes fragmented, and the fragments form vesicular structures called *microsomes*. Although the microsomes are artifacts, it is the practice to refer to the *microsomal drug metabolizing system* rather than to the smooth endoplasmic reticulum.

The microsomal system is peculiar in that both oxidations and reductions usually require the reducing cofactor NADPH (TPNH). This is because microsomal oxidations proceed by way of the introduction of oxygen rather than by dehydrogenation, and NADPH is essential to reduce one of the atoms of O₂. The drug first binds to an oxidized cytochrome P-450. The drug-cytochrome complex is then reduced by NADPH-cytochrome reductase; the reduced complex then combines with O₂, after which the metabolite is released and oxidized cytochrome P-450 is regenerated. Cytochrome P-450 is a generic term that includes at least six, and probably more, separate enzymes²⁹.

Some of the enzymes of the microsomal system are quite easily *induced*; that is, a substrate of the enzyme may considerably increase the activity of that enzyme by increasing the biosynthesis of that enzyme. An increase in the amount of smooth endoplasmic reticulum is also sometimes demonstrated concomitantly with enzyme induction.

Treatment of an experimental subject with phenobarbital will greatly increase the rate of metabolism of phenobarbital, which necessitates larger and more frequent doses of the drug in order to maintain a constant sedative effect. Moreover, phenobarbital may induce an increased metabolism of some other but not all barbiturates as well as some unrelated drugs, such as strychnine and warfarin. Oddly, warfarin does not readily induce its own biotransformation. At the present

time, both self-induction and cross-induction appear capricious and unpredictable.

Induction may create therapeutic problems. For example, the use of phenobarbital during treatment with warfarin increases the dose requirement for warfarin. If the physician is unaware of this interaction and fails to increase the dose, the patient may suffer a thrombotic episode. If the dose of warfarin has been increased and the phenobarbital is then discontinued, the rate of metabolism of warfarin may drop to its previous level, so that the patient is overdosed, with hemorrhagic consequences. Some drugs inhibit rather than induce the microsomal system, which reduces the dose requirement and may lead to toxicity. Cimetidine is an example of a drug that inhibits the hepatic metabolism of a number of other drugs.

The activity of the microsomal system is affected by many factors other than the presence of drugs. Age, sex, nutritional states, pathological conditions, body temperature, and genetic factors are among the influences that have been identified. Age, particularly, has received considerable attention. Infants have a poorly developed microsomal system, which accounts for the low dose requirement for morphine and also explains the high toxicity of chloramphenicol in infants.

The activity and selectivity of the microsomal system varies greatly from species to species, so that care must be exercised in extrapolating experimental findings in laboratory animals to man.

Types of Biotransformations—Biotransformations may be *degradative*, wherein the drug molecule is diminished to a smaller structure, or *synthetic*, wherein one or more atoms or groups may be added to the molecule. Very few drugs are degraded completely. However, it is more useful to categorize biotransformations with respect to "metabolic" (nonconjugative) biotransformations and conjugative biotransformations. The former is called phase I and the latter phase II. In phase I pharmacodynamic activity may be lost, however, active and chemically reactive intermediates may also be generated. The polarity of the molecule may or may not be increased sufficiently to increase excretion markedly. In phase II, metabolites from phase I may be conjugated, and sometimes the original drug may be conjugated, thus bypassing phase I. Phase II generates metabolites of high polarity which are readily excreted.

Biotransformations may be placed into five categories: (1) oxidation, (2) reduction, (3) hydrolysis, (4) conjugation, and (5) miscellaneous. Oxidation, reduction and hydrolysis comprise phase I. Conjugation comprises phase II. Most of the miscellaneous belong in phase I.

Oxidation—Oxidation is more common than any other type of biotransformation. Oxidations that occur primarily in the liver microsomal system include side-chain hydroxylation, aromatic hydroxylation, deamination (which is oxidative and results in the intermediate formation of RCHO), *N*-, *O*-, and *S*-dealkylation (which probably involves hydroxylation of the alkyl group followed by oxidation to the aldehyde), and sulfoxide formation. *N*-Demethylation involves a different system from *N*-dealkylation of higher radicals.

Oxidations that occur elsewhere than the microsomes are generally dehydrogenations followed by the addition of oxygen or water. Examples are the oxidation of alcohols by alcohol dehydrogenase, the oxidation of aldehyde by aldehyde dehydrogenase, and the deamination of monoamines by monoamine oxidase and diamines by diamine oxidase. The oxidation of purines like caffeine and theophylline is also extramicrosomal.

Reduction—Reductions are relatively uncommon. They mainly occur in liver microsomes, but they occasionally take place in other tissues. Examples are the reduction of nitro and nitroso groups (as in chloramphenicol, nitroglycerin, and organic nitrites), of the azo group (as in prontosil), and of certain aldehydes to the corresponding alcohols (as with the deaminated serotonin metabolite, 5-hydroxytryptophal, to 5-hydroxytryptophol).

Hydrolysis—Hydrolysis is a common biotransformation among esters and amides. Esterases are located in many structures besides the microsomes. For example, cholinesterases are found in plasma, erythrocytes, liver, nerve terminals, junctional interstices, and postjunctional structures, and procaine esterases are found in plasma. Various phosphatases and

sulfatases are also widely distributed in tissues and plasma, although few drugs are appropriate substrates. The hydrolytic deamidation of merperidine occurs primarily in the hepatic microsomes.

Conjugation—A large number of drugs or their metabolites are conjugated. Conjugation is the biosynthetic process of combining a chemical compound with a highly polar and water-soluble natural substance to yield a water-soluble, usually inactive, product. Conjugations generally involve either esterification, amidation, mixed anhydride formation, hemiacetal formation, or etherization.

Glucuronic acid is the most frequent partner to the drug in conjugation. Actually, the drug reacts with uridine diphosphoglucuronic acid rather than with simple glucuronic acid. The drug or drug metabolite combines at the number 1 carbon (aldehyde end) and not at the carboxyl end of glucuronic acid. The hydroxyl group of an alcohol or a phenol attacks the number 1 carbon of the pyran ring to replace uridine diphosphate. The product is a hemiacetyl-like derivative. Since the product is not an ester, the term *glucuronide* is appropriate. Rarely, thiols and amines may form analogous glucuronides.

Carboxyl compounds form esters, appropriately called *glucuronates*, in replacing the uridine diphosphate. *Sulfuric acid* is also a frequent conjugant, especially with phenols and to a lesser extent with simple alcohols. The sulfurated product is called an *etheral sulfate*. Occasionally sulfuric acid conjugates with aromatic amines to form *sulfamates*. *Phosphoric acid* also conjugates with phenols and aromatic amines. The conjugation of benzoic acid with glycine to yield hippuric acid is a classical example of an *amidation* conjugative process. Cysteine may take the place of glycine, through the intermediation of glutathione, to yield mercapturic acids with certain aromatic acids.

Amidations with amino acids are less frequent than *acetylation*, partly because few drugs are carboxylic compounds. Aromatic amines and occasionally aliphatic amines or heterocyclic nitrogen are frequently acetylated. Acetyl-CoA is the biological reagent rather than acetic acid itself. Unlike most other conjugates, the acetylate (amide) is usually less water-soluble than the parent compound. The acetylation of the para-amino group of the sulfonamides is a prime example of this type of conjugation.

Although most conjugations occur in the liver, the microsomal system is not involved. Some conjugations occur in the kidney or in other tissues.

Miscellaneous—Many amines, especially derivatives of β -phenylethylamine and heterocyclic compounds, are methylated in the body. The products are usually biologically active, sometimes more so than the parent compound. *N-Methylation* may occur in the cell sap of the liver and elsewhere, especially in chromaffin tissue in the case of phenylethylamines.

Phenolic compounds may be *O-methylated*. *O-Methylation* is the principal route of biotransformation of catecholamines such as epinephrine and norepinephrine, the methyl group being introduced on the meta hydroxy substituent. Both *N-* and *O-methylation* require *S-methyladenosyl* cysteine.

Desulfuration, in which oxygen may replace sulfur, takes place in the liver. Thiopental is in part converted to pentobarbital by desulfuration, and parathion is transformed to paraoxon.

Dehalogenation of certain insecticides and various halogenated hydrocarbons may take place, principally in the liver but not in the microsomes.

Excretion

Some drugs are not biotransformed in the body. Others may be biotransformed, but their products still remain to be eliminated. It follows that excretion is involved in the elimination of all drugs and/or their metabolites. Although the kidney is the most important organ of excretion, some substances are excreted in bile, sweat, saliva, gastric juice, or from the lungs.

Renal Excretion—The excretory unit of the kidney is called the *nephron* (Fig 37-14). There are several million nephrons in the human kidney. The nephron is essentially a filter funnel, called *Bowman's capsule*, with a long stem, called a *renal tubule*. It is also now recognized that the collecting duct is functionally a part of the nephron. The *blood vessels* that invest the capsule and the tubule are also an essential part of the nephron.

Bowman's capsule is packed with a tuft of branching interconnected capillaries (*glomerular tuft*), which provide a large surface area of capillary endothelium ("filter paper") through which fluid and small molecules may filter into the capsule and begin passage down the tubule. The glomerular tuft together with Bowman's capsule constitute the *glomerulus*. The glomerular capillary endothelium and the sup-




Fig 37-14. Diagram of a mammalian nephron. Note how the lower loops of the postglomerular capillaries course downward and double back along with the tubule. This allows countercurrent distribution to maintain hyperosmolar urine within the thin segment.

porting layer of Bowman's capsule have channels ranging upwards to 40 Å. Consequently, all unbound crystalloid solutes in plasma and even a little albumin pass into the glomerular filtrate.

The postglomerular vessels which lie close to the tubules are critically important to renal function in that substances resorbed from the filtrate by the tubule are returned to the blood along these vessels. The tubule is not straight but rather first makes a number of convolutions (called a *proximal convoluted tubule*), then courses down and back up a long loop (called the *loop of Henle*), makes more convolutions (the *distal convoluted tubule*), and finally joins the collecting duct. The loop of Henle is divided into a *proximal (descending) tubule*, a *thin segment*, and a *distal (ascending) tubule*.

As the glomerular filtrate passes through the proximal tubule, some solute may be resorbed (*tubular resorption*) through the tubular epithelium and returned to the blood. Resorption occurs in part by passive diffusion and in part by active transport, especially with sodium and glucose. Chloride follows sodium obligatorily.

In the proximal region, the tubule is quite permeable to water, so that resorbed solutes are accompanied by enough water to keep the resorbate isotonic. Consequently, although the filtrate becomes diminished in volume by approximately 80% in the proximal tubule, it is not concentrated.

Some *acidification* occurs in the proximal tubule as the result of carbonic anhydrase activity in the tubule cells and the diffusion of hydronium ions into the lumen. In the lumen the hydronium ion reacts with bicarbonate ion, which is converted to resorbable nonionic CO₂.

There is also active transport of organic cations and anions into the lumen (*tubular secretion*), each by a separate system. These active transport systems are extremely important in the excretion of a number of drugs; for example, penicillin G is rapidly secreted by the anion transport system and tetraethylammonium by the cation transport system. Probenecid is an inhibitor of anion secretion and hence decreases the rate of loss of penicillin from the body.




Fig 37-15. The effect of urinary pH on the mean cumulative excretion in man of mecamylamine during the first day after oral administration of 10 mg. Vertical broken lines: standard deviation (courtesy, Milne, et al³⁰).

As the filtrate travels through the thin segment it becomes concentrated, especially at the bottom, as a result of active resorption and a countercurrent distribution effect enabled by the recurrent and parallel arrangement of the ascending segment, the parallel orientation of the collecting duct, and the similar recurrent geometry of the associated capillaries. In the thick segment of the ascending loop of Henle, both sodium and chloride are transported actively.

In the distal tubule sodium resorption occurs partly in exchange for potassium (*potassium secretion*) and for hydronium ions. Adrenal mineralocorticoids promote distal tubular sodium resorption and potassium and hydronium secretion. *Ammonia secretion* also occurs, so that the urine may be either acidified or alkalized, according to acid-base and electrolyte requirements.

Water is resorbed selectively from the distal end of the distal convoluted tubule and the collecting ducts; water resorption is under the control of the antidiuretic hormone.

Drugs may also be resorbed in the distal tubule; the pH of the urine there is extremely important in determining the rate of resorption, in accordance with the principle of nonionic diffusion and pH partition. The pH of the tubular fluid also affects the tubular secretion of drugs.

As an example of the importance of urine pH, in humans the secondary amine, mecamylamine, is excreted more than four times faster when the urine pH is less than 5.5 than when it is above 7.5; Fig 37-15 illustrates the effect of urine pH on the excretion of this amine. The effect of urine pH on the excretion of a weak acid, sulfaethidole (for structure, see page 1109, RPS-15), is shown in Fig 37-16.

The urine pH and hence drug excretion may fluctuate widely according to the diet, exercise, drugs, time of day, and other factors. Obviously, the excretion of weak acids and bases can be partly controlled with acidifying or alkalinizing salts, such as NH_4Cl or NaHCO_3 , respectively. Comparative studies on potency and efficacy in man have demonstrated the importance of controlling urinary pH. Urine pH is important only when the drug in question is a weak acid or base of which a significant fraction is excreted. The plasma levels will change inversely to the excretory rate. For example, it has been shown clinically with quinidine that alkalinization of the urine not only decreases the urine concentration but increases the plasma concentration and toxicity.

The collecting duct also resorbs sodium and water, secretes potassium, acidifies, and concentrates the urine. Antidiuretic hormone (ADH) controls the permeability to water of both the collecting duct and the distal tubule.




Fig 37-16. The effect of urinary pH on the excretion of sulfaethidole in a human subject after oral administration of 2 g. Bars (lower half): urinary pH; circles (open and closed, top): log of the amount of drug remaining in the body; negative slopes (of lines defined by the circles): a function of the rate constant of excretion. Note the abrupt increase in rate when the urinary pH is changed from acidic to neutral or slightly alkaline (courtesy, Kostenbauder, et al³¹).

Renal clearance and the kinetics of renal elimination are discussed in Chapter 38 (page 746).

Biliary Excretion and Fecal Elimination—Many drugs are secreted into the bile and thence pass into the intestine. A drug that is passed into the intestine via the bile may be reabsorbed and not lost from the body. This cycle of biliary secretion and intestinal resorption is called *enterohepatic circulation*. Examples of drugs enterohepatically circulated are morphine and the penicillins. The biliary secretory systems greatly resemble those of the kidney tubules. The enterohepatic system may provide a considerable reservoir for a drug.

If a drug is not completely absorbed from the intestine, the unabsorbed fraction will be eliminated in the feces. An unabsorbable drug that is secreted into the bile will likewise be eliminated in the feces. Such fecal elimination is also called *fecal excretion*. Only rarely are drugs secreted into the intestine through the succus entericus (intestinal secretions), although a number of amines are secreted into gastric juice.

Alveolar Excretion—The large alveolar area and high blood flow make the lungs ideal for the excretion of appropriate substances. Only volatile liquids or gases are eliminated from the lungs. Gaseous and volatile anesthetics are essentially completely eliminated by this route. Only a small amount of ethanol is eliminated by the lungs, but the concentration in the alveolar air is so constantly related to the blood alcohol concentration that the analysis of expired air is acceptable for legal purposes. The high aqueous solubility and relatively low vapor pressure of ethanol at body temperature account for the retention of most of the substance in the blood. Carbon dioxide from those drugs that are partly degraded to CO_2 also is excreted in the lungs.

Pharmacokinetics

Pharmacokinetics is the science that treats of the rate of absorption, extent of absorption, rates of distribution among body compartments, rate of elimination, and related phenomena. Because of its importance, two chapters, *Basic Pharmacokinetics* (page 741) and *Principles of Clinical Pharmacokinetics* (page 762), have been devoted to the subject.

Drug Interaction and Combination

It is frequent that a patient may receive more than one drug concurrently. Case records show that surgical patients commonly receive more than 10 and sometimes as many as 30 drugs and that the patient is often under the influence of several drugs at once, sometimes unnecessarily. Multiple-drug administration is also common to patients hospitalized for infections and for many other disorders. Furthermore, a patient may be suffering from more than one unrelated disorder which demands simultaneous treatment with two or more drugs. In such instances interactions are unsolicited and often unexpected.

In addition to the administration of drugs concurrently for their independent and unrelated effects, drugs are sometimes administered concurrently deliberately to make use of expected interactions.

Types of Interaction and Reasons for Combination Therapy

A drug may affect the response to another drug in a quantitative way. On the one hand, the intensity of either the therapeutic effect or side effect may be augmented or suppressed. On the other hand, a qualitatively different effect may be brought out. The mechanisms of such interactions are many and are not always understood. A drug may not necessarily affect either the quality or initial intensity of effect of another drug but may cause significant to profound changes in the duration of action. The nature of this type of interaction is generally fairly well understood, although it may not yet have been ascertained for any particular drug combination. The deliberate use of combined interacting drugs is most valid when the mechanism of the interaction is understood and the combined effects are both quantifiable and predictable. The rationales of drug combination and the principles involved are discussed below.

Combinations to Increase Intensity of Response or Efficacy—Sometimes the basis for the action of one drug to increase the intensity of response to another is well understood, but often the reason for a positive interaction is obscure. A terminology has grown up that is frequently not enlightening as to mechanisms and principles but also which is somewhat confusing.

Drugs that elicit the same quality of effect and are mutually interactive are called *homergic*, regardless of whether there is anything in common between the separate response systems. Thus the looseness of the term admits a pressor response consequent to an increase in cardiac output to be homergic with one resulting from arteriolar constriction, even though there is not one common responsive element, the blood pressure itself being but a passive indicator. However, homergic drugs usually have in common at least part of a response system. Thus both norepinephrine and pitressin stimulate some of the same vascular smooth muscle, even though they do not excite the same receptors.

Two homergic drugs can be agonists of the same receptor, so that the entire response system is common to both. Such drugs are called *homodynamic*. As discussed under *Drug Receptors and Receptor Theory* (page 718), homodynamic drugs will generate dose-intensity of effect curves with parallel slopes but not necessarily with identical maxima or efficacies, if one of the drugs is a partial agonist.

From mass law kinetics and dose-effect data of the separate drugs it is possible to predict the combined effects of two agonists to the same receptor. If both drugs are full agonists, theory predicts that an ED_x of Drug A added to an ED_y of Drug B should elicit the same effect as that of an ED_y of Drug A added to an ED_x of Drug B. An example is shown in Fig

37-17. Dose-percent data with homodynamic drugs can be treated in the same way.³³

Drugs whose combined effects fit the above conditions are called *additive*. If the response to the combination exceeds the expected value for additivity, the drugs are considered to be *supra-additive*. Purely homodynamic drugs do not show supra-additivity; however, if one drug in the pair has an additional action to affect the concentration or penetrance of the other or to prime the response system in some way, two agonists to the same receptor may exhibit supra-additivity. Two homergic drugs are *infra-additive* if their combined effect is less than expected from additivity. As with supra-additivity, infra-additivity must involve an action elsewhere than on a common receptor.

Two drugs are said to be *summative* if a dose of drug that elicits response x added to a dose of another drug that elicits response y gives the combined response $x + y$. Very little significance can usually be attached to summation. Unless the dose-intensity curve of each drug is linear rather than log-linear, summation cannot be predicted from the two curves. When summation does occur with the usual clinical doses of two drugs, it almost never occurs over the entire dose range; indeed, if the dose of each of the two drugs is greater than an ED_{50} , summation is theoretically impossible unless it is possible to increase the maximal response. At best, summation is an infrequent clinical finding limited to one or two doses.

Two drugs are said to be *heterergic* if the drugs do not cause responses of the same quality. When heterergy is positive, ie, the response to one drug is enhanced by the other, *synergism* is said to occur. The word has often been used to describe any positive interaction, but it should be used only to describe a positive interaction between heterergic drugs. The term *potentiation* has been used synonymously with synergism, but misuse of the term has led to the recommendation that the term be dropped. Synergism is often the result of an effect to interfere with the elimination of a drug and thus to increase the concentration; synergism may also result from an effect on penetrance or upon the responsivity of the effector system. Examples of a synergistic effect in which responsivity is enhanced are the action of adrenal corticoids to enhance the vasoconstrictor response to epinephrine and the increase of




Fig 36-17. Additive inhibitory effects of tetraethylammonium (TEA) and hexamethonium (C6) on the superior cervical ganglion of the cat. The theoretical line for additivity was calculated on the basis that an increment of TEA added to an ED_x of C6 should have the same effect as if it were added to an ED_x of TEA. When TEA and C6 were administered together, an equal amount of each was given. The dose is the sum of the doses of the two components (courtesy, Harvey³²).

TEVA EXHIBIT 1030

epinephrine-induced hyperglycemia consequent to impairment by theophylline of the enzymatic destruction of the cyclic-AMP which mediates the response.

In clinical practice two homodynamic drugs are rarely coadministered for the purpose of increasing the response, since a sufficient dose of either drug should be able to achieve the same effect as a combination of the two. Most clinical combinations with positively interacting drugs are with heterergic drugs.

Combinations to Decrease Individual Doses and Toxicity—When homodynamic drugs are coadministered, it is usually for the purpose of decreasing toxicity. If the toxicities of two homodynamic drug are infra-additive, the toxicity of combined partial doses of the two drugs will often be less than with full doses of either drug. This principle is valid for trisulfapyrimidines mixture (see page 1176).

Combinations to Attack a Disease Complex at Different Points—With many diseases more than one organ or tissue may be affected or events at more than one locus may bear upon the ultimate perturbation. For example, in duodenal ulcer, psychic factors appear to increase activity in the vagus nerve which modulates gastric secretion, so that it was rational to explore the effects of sedatives, ganglionic blocking drugs, antimuscarinic drugs, and antacids, singly and in combination. In heart failure the decrement in renal plasma flow and changes in aldosterone levels promote the retention of salt and water, so that diuretics and digitalis are usually employed concomitantly. Pain, anxiety, and agitation or depression are frequent accompaniments of various pathologic processes, so that it is to be expected that analgesics, tranquilizers, sedatives or antidepressives will frequently be given at the same time, along with other drugs intended to correct the specific pathology.

Combinations to Antagonize Untoward Actions—The side effects of a number of drugs can be prevented or suppressed by other drugs. An antagonist may compete with the drug at the receptor that initiates the side effect, depress the side-effector system at a point other than the receptor, or stimulate an opposing system.

Antagonism at the receptor is *competitive antagonism* if the antagonist attaches at the same receptor group as the agonist (see page 719). Antagonism at a different receptor group or inhibition elsewhere in the response system is *non-competitive antagonism*. Both competitive and noncompetitive antagonism are classified as *pharmacological antagonism*. The stimulation of an opposing system is *physiological antagonism*.

Clinical examples of pharmacological antagonism are the use of atropine to suppress the muscarinic effects of excess acetylcholine consequent to the use of neostigmine and the use of antihistaminics to prevent the effects of histamine liberated by tubocurarine. Examples of physiological antagonism are the use of amphetamine to correct partially the sedation caused by anticonvulsant doses of phenobarbital and the administration of ephedrine to correct hypotension resulting from spinal anesthesia.

Combinations That Affect Elimination—Only a few drugs are presently used purposefully to elevate or to prolong plasma levels by interfering with elimination, although continued interest in such drugs will probably increase the number.

Probenecid, which has already been mentioned to antagonize the renal secretion of penicillin, was originally introduced for this purpose. However, the inexpensiveness of penicillin G, repository preparations of penicillin G, and oral preparations (which obviate the need for injection) make it less imperative to retard the excretion of penicillin. The low non-allergenic toxicity of penicillin permits very large doses to be given without concern for the high plasma concentrations that result, which also means that there is little necessity for in-

creasing the biological half-life of the drug. Consequently, probenecid routinely is not used much today in combination with penicillin.

The use of vasoconstrictors to increase the sojourn of local anesthetics at the site of infiltration continues, but few other clinical examples of the deliberate use of one drug to interfere with either the distribution or elimination of another can be cited. Nevertheless, the subject of the effect of one drug on the elimination of another has become immensely active. Innumerable drugs affect the fate of others, and the therapist must be aware of such interactions.

Drugs that induce cytochrome P-450s enhance the elimination of drugs that are metabolized by the liver microsomes. There would be very little point ordinarily to solicit combinations that would shorten the duration of action or lower plasma levels unless it were to reduce an overdosage. However, since such combinations are unwittingly or unavoidably used, this type of interaction is of great clinical importance.

Combinations to Alter Absorption—In the section on *Vehicles and Absorption Adjuvants* (page 730) it was mentioned that certain substances facilitate the absorption of others. The use of such absorption adjuvants is generally included under the subject of formulation rather than under drug combination. Although drugs which increase blood flow, motility, etc have an effect to increase the rate of absorption, the use of such drugs has so far not proven to be very practical. When it is desired to slow the absorption of drugs, various physical or physicochemical means prove to be more effective and less troublesome than drug combinations.

Fixed Combinations of Drugs

Concomitant treatment with two or more drugs is frequently unnecessary, and it generally immeasurably complicates therapy and the evaluation of response and toxicity. Nevertheless, it is often warranted, even essential, and cannot be condemned categorically. However, with fixed-dose or fixed-ratio combinations, in which the drugs are together in the same preparation, have certain disadvantages, except for a few rare instances like trisulfapyrimidines.

The disadvantages are as follows: patients differ in their responsivity or sensitivity to drugs, and adjustments in dosage or dose-interval may be necessary. If adjustment of only one component of the mixture is required, it is undesirable that the schedule of the second component be obligatorily adjusted, as it is in a fixed combination. According to which way the dose is adjusted, either toxicity or loss of the therapeutic effect may result. Furthermore, when adverse effects to either component occur, both drugs must be discontinued. The fixed combination denies the physician flexible control of therapy. Especially when one component in a mixture is superfluous yet potentially toxic, as is often the case, the promotion of fixed combinations is reprehensible. However, the separate administration of drugs used in combination often complicates treatment for the patient, who, in an outpatient situation and sometimes in the hospital, may not take all of his medication or who may take it at inappropriate intervals. The resulting consequences may be worse than those of fixed combinations in certain instances. Consequently, a summary dismissal of fixed combinations is unwarranted. Rather, the fundamentals of pharmacokinetics and clinical experience must be brought together with biopharmaceutics to analyze present combinations and to predict possible new allowable combinations.

Dangers in Multiple-Drug Therapy

Some objections to fixed-dose combinations were stated above. Also the unanticipated effects of drug combinations

have been touched upon, particularly with respect to effects upon elimination. But it should be made clear that more is at stake than simply the biological half-life of a drug. On page 733 was given an example of the grave clinical consequences of the effect of phenobarbital to enhance the biotransformation of warfarin. Other examples of dangerous interactions, such as the effect of several antidepressants greatly to synergize catecholamines, may be cited. Even some antibiotics antagonize each other and increase mortality.

In addition to the obvious pitfalls posed by the interactions themselves, the use of multiple-drug therapy fosters careless diagnosis and a false sense of security in the number of drugs employed. Multiple-drug therapy should never be employed without a convincing indication that each drug is beneficial beyond the possible detriments or without proof that a therapeutically equivocal combination is definitely harmless. Finally, the expense to the patient warrants consideration.

References

1. Clark AJ: *J Physiol (London)* 61: 547, 1926.
2. Waud DR: *Pharmacol Rev* 20: 49, 1968.
3. Ariens EJ, ed: *Molecular Pharmacology*, vol 1, Academic, New York, 176-193, 1964.
4. Stephenson RP: *Brit J Pharmacol* 11: 379, 1956.
5. McKay DJ: *J Pharm Pharmacol* 18: 201, 1966.
6. Furchgott RF: *Ann Rev Pharmacol* 4: 21, 1964.
7. Rang HP: *Brit J Pharmacol* 48: 475, 1973.
8. Colquhoun D: The relation between classical and cooperative models for drug action. In Rang HP, ed: *Drug Receptors*: University Park, Baltimore, 1973.
9. Cuatrecasas P, Greaves MF, eds: *Receptors and Recognition*, Halsted, New York, 1976.
10. Danielli JF, et al, eds: *Fundamental Concepts in Drug-Receptor Interactions*, Academic, New York, 1970.
11. DeRobertis E: *Synaptic Receptors, Isolation and Biology*, Dekker, New York, 1975.
12. DeRobertis E, Schacht J, eds: *Neurochemistry of Cholinergic Receptors*, Raven, New York, 1974.
13. Porter R, O'Connor M, eds: *Molecular Properties of Drug Receptors*, Churchill, London, 1970.
14. Robson JM, Stacey RS: Drug-Receptor Theories. In *Recent Advances in Pharmacology*, Little, Brown, Boston, 1968. Chapter 4.
15. Triggler DJ, et al, eds: *Cholinergic Ligand Interactions*, Academic, New York, 1971.
16. Triggler DJ: *Neurotransmitter-Receptor Interactions*, Academic, London, 1971.
17. Rang HP, ed: *Drug Receptors*, University Park, Baltimore, 1973.
18. Schanker LS: *Advan Drug Res* 1: 71, 1964.
19. Brodie BB, et al: *J Pharmacol Exp Ther* 130: 20, 1960.
20. Tritt EB, et al: *J Pharmacol Exp Ther* 100: 309, 1950.
21. Lillehei JP: *J Am Med Assoc* 205: 531, 1963.
22. Martin AN, et al: *Physical Pharmacy*, 2nd ed, Lea & Febiger, Philadelphia, 247, 253, 1969.
23. Jacobs MH: *Cold Spring Harbor Symp Quant Biol* 8: 30, 1940.
24. Schanker LS: *Pharmacol Rev* 14: 501, 1961.
25. Brodie BB, Hogben CA: *J Pharm Pharmacol* 9: 345, 1957.
26. Hogben CA: *Proc Fed Am Soc Exp Biol* 19: 864, 1960.
27. Albert A: *Pharmacol Rev* 4: 136, 1952.
28. Ariens EJ, et al: In Ariens, EJ, ed. *Molecular Pharmacology*, vol 1, Academic, New York, 7-52, 1964.
29. Lu AYH, West SB: *Pharmacol Rev*, 31: 277, 1980.
30. Milne MD, et al: *Clin Sci* 16: 599, 1957.
31. Kostenbauder HB, et al: *J Pharm Sci* 51: 1084, 1962.
32. Harvey SC: *Arch Intern Pharmacodyn* 114: 232, 1958.
33. Weaver LC, et al: *J Pharmacol Exp Ther* 113: 359, 1955.

Bibliography

- Albert A: *Selective Toxicity*, 6th ed, Chapman and Hall, London, 1979.
- Albert A: *The Selectivity of Drugs*, Chapman and Hall, London, 1975.
- Ariens EJ, ed: *Drug Design*, vols 1 and 2, Academic, New York, 1971.
- Ariens EJ, ed: *Drug Design*, vol 5, Academic, New York, 1975.
- Ariens EJ, ed: *Molecular Pharmacology*, vol 1, Academic, New York, 1964.
- Ariens EJ, ed: *Physico-Chemical Aspects of Drug Action*, Pergamon, London, 1968.

Barlow RB: *Quantitative Aspects of Chemical Pharmacology*, University Park, Baltimore, 1980.

Berridge MJ: Receptors and Calcium Signalling, *TIPS* 1982: 419.

Binns TB, ed: *Absorption and Distribution of Drugs*, Livingston, London, 1964.

Boeynaems JM, Dumont JE, eds: *Outlines of Receptor Theory*, Elsevier/North Holland, Amsterdam, 1980.

Brodie BB, Hogben CA: Some physicochemical factors in drug action, *J Pharm Pharmacol* 9: 345, 1957.

Capaldi RA, ed: *Membrane Proteins and their Interaction with Lipids*, Dekker, New York, 1977.

Cuatrecasas P, Greaves MF, eds: *Receptors and Recognition*, Halsted, New York, 1976.

DeRobertis E: *Synaptic Receptors, Isolation and Biology*, Dekker, New York, 1975.

Featherstone RM, ed: *A Guide to Molecular Pharmacology*, Parts I and II, Dekker, New York, 1973.

Fineman JB, Michell RH, eds: *Membrane Structure*, Elsevier/North Holland, Amsterdam, 1981.

Fink BR, ed: Molecular mechanisms of anesthesia. *Progr Anesthesiol* 1: 1-652, 1975.

Goldstein A: The interactions of drugs and plasma proteins. *Pharmacol Rev* 1: 102, 1949.

Goldstein A, et al: *Principles of Drug Action*, 3rd ed, Wiley, New York, 1985.

Gregoriadis G, et al: *Targeting of Drugs*, Plenum, New York, 1982.

Hartiala H: Metabolism of hormones, drugs, and other substances in the gut. *Physiol Rev* 53: 496, 1973.

Hogben CAM, Lindgren P, eds: *Drugs and Membranes*, Macmillan, New York, 1963.

Jakoby WB, et al: *Metabolic Basis of Detoxification*, Academic, New York, 1982.

Jenner P, Testa B, eds: *Concepts in Drug Metabolism*, Part A, Dekker, New York, 1980.

Jenner P, Testa B, eds: *Concepts in Drug Metabolism*, Part B, Dekker, New York, 1981.

Kotyk A, Janáček K, eds: *Membrane Transport*, vol 9, of *Biomembranes*, Plenum, New York, 1977.

Kreuzer F, Slegers JFG, eds: *Passive Permeability of Cell Membranes*, Plenum, New York, 1972.

Kunos G, ed: *Adrenoreceptors and Catecholamine Action*, Part A, Wiley Interscience, New York, 1981.

Lamble JW, ed: *Towards Understanding Receptors*, Elsevier/North Holland, Amsterdam, 1981.

Lamble JW, ed: *More About Receptors*, Elsevier/North Holland, Amsterdam, 1982.

Lefkowitz RJ, ed: *Receptor Regulation*, Chapman and Hall, London, 1981.

Lefkowitz RJ, et al: Mechanism of Hormone-Receptor-Effector Coupling: The B-Adrenergic Receptor and Adenylate Cyclase, *Proc Fed Am Soc Exptl Biol* 41: 2664, 1982.

Levine RR: *Pharmacology: Drug Actions and Reactions*, 2nd ed, Little, Brown, New York, 1978.

Levine RR, Pelikan EW: Mechanisms of drug absorption and excretion. Passage of drugs out and into the gastrointestinal tract. *Ann Rev Pharmacol* 4: 69, 1964.

Levitzki A: Activation and Inhibition of Adenylate Cyclase by Hormones: Mechanistic Aspects, *TIS* 1982: 203.

Martonosi AN: *Membranes and Transport*, Plenum, New York, 1982.

Meyer UA: Role of Genetic Factors in the Rational Use of Drugs, Chapter 18 in, Melmon KL, Morrelli, HF, eds: *Clinical Pharmacology*, 2nd ed, Macmillan, New York, 1978.

Milne MD: Nonionic diffusion and excretion of weak acids and bases. *Am J Med* 24: 709, 1958.

Nebert DW, et al: Genetic Mechanisms Controlling the Induction of Polysubstrate Monooxygenase (P-450) Activities, in *Ann Rev Pharmacol Toxicol* 21: 431, 1981.

Park DV, Smith RL, eds: *Drug Metabolism—From Microbes to Man*, Taylor & Francis, London, 1977.

O'Brien RD, ed: *The Receptors*, vol 1. *General Principles and Procedures*, Plenum, New York, 1979.

Rang HP, ed: *Drug Receptors*, University Park, Baltimore, 1973.

Roberts GCK: *Drug Action at the Molecular Level*, University Park, Baltimore, 1977.

Sandler M, ed: *Enzyme Inhibitors as Drugs*, University Park, Baltimore, 1980.

Schanker LS: Passage of drugs across body membranes. *Pharmacol Rev* 14: 501, 1961.

Schanker LS: Physiological transport of drugs. *Advan Drug Res* 1: 71, 1964.

Seeman P: The membrane actions of anesthetics and tranquilizers. *Pharmacol Rev* 24: 583-655, 1972.

Smythes JR, Bradley RJ, eds: *Receptors in Pharmacology*, Dekker, New York, 1978.

Stenlake JB: *The Chemical Basis of Drug Action*, Athlone, London, 1979.

- Symposium (various authors; Anton AH, Solomon HM, eds): *Drug-Protein Binding*. *Ann NY Acad Sci* 226:1-362, 1973.
- Triggle DJ: *Neurotransmitter-Receptor Interactions*, Academic, New York, 1971.
- Usdin E, et al: *Neuroreceptors*, Wiley & Sons, Chichester, 1981.
- Van Rossum JM, ed: *Kinetic of Drug Action*, Springer-Verlag, Berlin, 1977.
- Vesell E: Pharmacogenetics. *Biochem Pharmacol* 24: 445, 1975.
- Vesell ES: The influence of host factors on drug response. I. Ethnic background, *Rational Drug Ther* 13, no 8: 1, 1979.
- Weissman G, Claiborne R, eds: *Cell Membranes: Biochemistry, Cell Biology and Pathology*, HP Publishing, New York, 1975.
- Yamamura HI, et al, eds: *Neurotransmitter-Receptor Binding*, Raven, New York, 1978.